1 
  
Study Protocol and Statistical Analysis Plan  for the Randomized Evaluation of Trial Acceptance by 
[CONTACT_111505] (RETAIN) study  
Two randomized controlled trials of financial incentives embedded within two separate parent 
trials that together examine whether offers of money increase enrollment rates or lead to ethical 
problems . 
 
 
 
Spon sor                                                                 National  Institute s of Health : National Cancer Institute                   
 
NIH Grant  Number                1RO1CA197332- 01 
 
 
Local Protocol                                  823491 
Study Registry ID: [REMOVED] 
Document Date :                    08.06.2020
                                                                                                                        
Coordinating Center:                                                                     University of 
Pennsylvania  
 
Principal  Investigator                                                   [INVESTIGATOR_73808] D. Halpern , MD , PhD  
Perelman School of Medicine at the University of Pennsylvania  
[ADDRESS_124133]  
Philadelphia, PA [ZIP_CODE]  
Phone: 215 -898-1462  
Email: shalpern@  upenn.ed u 
 
The RETAIN Study: Protocol and Statistical Analysis Plan  
 
[ADDRESS_124134] remuneration  ........................................................................................................... 26 
i. RTOG 1308  .................................................................................................................................................. 26 
ii. BASC  ........................................................................................................................................................... 26 
iii. MOVE IT  ..................................................................................................................................................... 26 
e. Payment Equalizat ion ........................................................................................................... 26 
7. Randomization  .......................................................................................................................... 27 
a. Groups  .................................................................................................................................. 27 
b. Assignment  ........................................................................................................................... 27 
i. RTOG 1308  .................................................................................................................................................. 28 
ii. BASC  ........................................................................................................................................................... 28 
iii. MOVE IT  ..................................................................................................................................................... 28 
8. Study Procedures  ...................................................................................................................... 28 
a. Screening  .............................................................................................................................. 28 
b. Eligibility  .............................................................................................................................. 29 
c. Inclusion of Wo men and Minorities  ...................................................................................... 29 
The RETAIN Study: Protocol and Statistical Analysis Plan  
 
3 
 d. Informed Consent for RETAIN in RTOG 1308  .................................................................... 29 
e. Informed Consent for RETAIN in BASC and MOVE IT  ..................................................... 30 
f. Administration of Survey Instruments  ................................................................................. 30 
i. RTOG 1308  .................................................................................................................................................. 30 
ii. BASC  ........................................................................................................................................................... 31 
iii. MOVE IT  ..................................................................................................................................................... 32 
g. Parent Trial Informed Consent (RTOG 1308, BASC, and MOVE IT)  .................................. [ADDRESS_124135] Members  ....................................................................... 42 
c. Stoppi[INVESTIGATOR_1869]  ...................................................................................................................... 43 
d. Adverse Events  ..................................................................................................................... 44 
e. Clinicaltrials.gov  ................................................................................................................... 44 
12. Human Subjects Protection  ...................................................................................................... 44 
a. Potential Study Risks  ............................................................................................................ 44 
b. Potential Study Benefits  ........................................................................................................ 45 
c. Risk/Benefit Analysis  ............................................................................................................ [ADDRESS_124136] 21, 2017 ........................................................................................................ 52 
a. Phase I –  Removal of the University of Pennsylvania as a Recruiting Site  ............................ 52 
b. Phase II – Modification to BASC recruitment script  ............................................................ 52 
The RETAIN Study: Protocol and Statistical Analysis Plan  
 
[ADDRESS_124137] 30, 2017 ........................................................................................................ 52 
a. Phase I –  Removal of the Healthcare System Distrust Scale  .................................................. 52 
b. Phase II – Modification to BASC screening procedures  ........................................................ 52 
c. Phases II and III -   Modification to the BASC and MOVE -IT debriefing scripts  .................. 53 
3. Approved September 26, 2017  .................................................................................................. 53 
a. Phases II and III -  Modifications to the Compared  Riskiness Scale  ...................................... 53 
4. Approved October 25, 2017 ...................................................................................................... 53 
a. Phases II and III – Clarification of Payment Procedures  ...................................................... 53 
5. Approved November 20, 2017  ................................................................................................... 54 
a. Phase II – Revision of BASC Debriefing Script  ..................................................................... 54 
b. Phase II -   BASC Waiver of HIPPA Authorization  ............................................................... 54 
c. Phase II – Revision to Compared Riskiness Scale for BASC study  ....................................... 54 
6. Approved January 3, 2018 ........................................................................................................ 55 
a. Phase I –  Termination of RTOG 1308 Collaboration  ............................................................ 55 
7. Approved January 25, 2018 ...................................................................................................... 55 
a. Phase II – Modification to BASC screening procedures  ........................................................ 55 
b. Phases II and III -    Revisions to the Compared Riskiness Scale  ........................................... 56 
8. Approved February 21, 2018 .................................................................................................... 56 
a. Phase II – Modification to MOVE IT recruitment procedures .............................................. 56 
b. Phases II and III – Modifications to the Compared Riskiness Scale  ...................................... 56 
9. Approved April 23, 2018  ........................................................................................................... 56 
a. Phase III – Modification to data collection and administration of surveys  ............................ 56 
10. Approved January 25, 2019 ...................................................................................................... 57 
a. Phase III – Addition of Qualitative Evaluation of Patient Decision -Making  ......................... [ADDRESS_124138]  .................................................................................................................................... 58 
2. Background and Significance  .................................................................................................... 58 
3. Objectives .................................................................................................................................  60 
a. Aims  ..................................................................................................................................... 60 
b. Primary Outcome Variable ................................................................................................... 61 
c. Secondary Outcome Variables  .............................................................................................. 61 
4. Study Organization  ................................................................................................................... 62 
a. RETAIN Infrastructure  ........................................................................................................ 62 
b. Research Team  .................................................................................................................... 63 
c. Participating  Parent Trial Sites ............................................................................................ 64 
5. Study Design  ............................................................................................................................. 65 
a. BASC Schema  ....................................................................................................................... 65 
b. MOVE IT Schema  ................................................................................................................ 66 
c. Key Study Des ign Elements across Parent Trials  .................................................................. 67 
d. Duration  ............................................................................................................................... 68 
i. BASC  ........................................................................................................................................................... 68 
The RETAIN Study: Protocol and Statistical Analysis Plan  
 
[ADDRESS_124139] remuneration  ........................................................................................................... 69 
i. BASC  ........................................................................................................................................................... 69 
ii. MOVE IT  ..................................................................................................................................................... 70 
e. Payment Equalization  ........................................................................................................... 70 
7. Randomization  .......................................................................................................................... 70 
a. Groups  .................................................................................................................................. 70 
b. Assignment  ........................................................................................................................... 71 
i. BASC  ........................................................................................................................................................... 71 
ii. MOVE IT  ..................................................................................................................................................... 71 
8. Study Procedures  ...................................................................................................................... 72 
a. Screening  .................................................................................................................................. 72 
a. Eligibility  .............................................................................................................................. 72 
b. Inclusion of Women and Minorities  ...................................................................................... 72 
c. Informed Consent for RETAIN in BASC and MOVE IT  ..................................................... 72 
d. Administration of Survey Instruments  .................................................................................. 73 
i. BASC  ........................................................................................................................................................... 73 
ii. MOVE IT  ..................................................................................................................................................... 74 
e. Parent Trial Informed Consent (BASC, and MOVE IT)  ...................................................... [ADDRESS_124140] Members  ....................................................................... 82 
c. Stoppi[INVESTIGATOR_1869]  ...................................................................................................................... 83 
d.  Adverse Even ts ........................................................................................................................ 83 
e. Clinicaltrials.gov  ................................................................................................................... 84 
12. Human Subjects Protection ...................................................................................................... 84 
a. Potential Study Risks  ............................................................................................................ 84 
b. Poten tial Study Benefits  ........................................................................................................ 85 
The RETAIN Study: Protocol and Statistical Analysis Plan  
 
6 
 c. Risk/Benefit Analysis  ............................................................................................................ 85 
d. Protective Measures  .............................................................................................................. 85 
i.  BASC  ................................................................................................................................................................ 86 
ii.  MOVE IT  ........................................................................................................................................................ 86 
e. Additional Protec tive Measures  ............................................................................................ 86 
13. References .................................................................................................................................  87 
IV. Original Statistical Analysis Plan  .................................................................................. 91 
1. Background and rationale  ........................................................................................................ 91 
2. Objectives and hypotheses  ........................................................................................................ 91 
3. Design and randomization ........................................................................................................ 91 
a.   BASC Trial  ............................................................................................................................. 92 
b. MOVE IT Trial  .................................................................................................................... 92 
4. Population .................................................................................................................................  92 
5. Primary outcome and analytic method  ..................................................................................... 93 
a. Primary outcome  .................................................................................................................. 93 
b. Primary analytic sample  ....................................................................................................... 93 
c. Primary analysis  ................................................................................................................... 93 
6. Approach to missing data & sensitivity analyses  ....................................................................... 95 
7. Secondary Outcomes ................................................................................................................. 96 
a. Outcome m easures  ................................................................................................................ 96 
b. Analysis of secondary outcomes  ............................................................................................ 97 
8. Sample  size and statistical power calculations  ........................................................................... 98 
a. Sample size  ........................................................................................................................... 98 
b. Statistical pow er calculations  ................................................................................................ 98 
9. Data Safety & Monitoring Board (DSMB)  ................................................................................ 98 
10. Stoppi[INVESTIGATOR_1869]  .......................................................................................................................... 99 
11. Timing of analysis and adjustment of significance level  ............................................................ 99 
12. Personnel  .................................................................................................................................. 99 
V. Changes to Statistical Analysis Plan  ............................................................................... 101 
VI. Final Statiscal Analysis Plan  ........................................................................................ 103 
1. Background and rationale  ...................................................................................................... 103 
2. Objectives and hypotheses  ...................................................................................................... 103 
3. Design and randomization ...................................................................................................... 103 
a.   BASC Trial  ........................................................................................................................... 103 
b. MOVE IT Trial  .................................................................................................................. 104 
4. Population ............................................................................................................................... 104 
5. Primary outcome and analytic method  ................................................................................... 105 
a. Primary outcome  ................................................................................................................ 105 
b. Primary analytic sample  ..................................................................................................... 105 
c. Primary analy sis ................................................................................................................. 105 
6. Secondary analysis  .................................................................................................................. 107 
The RETAIN Study: Protocol and Statistical Analysis Plan  
 
7 
 a. Approach to outliers and influential observations  ............................................................... 107 
b. Secondary outcome measures  ............................................................................................. 107 
c. Analysis of secondary outcomes  .......................................................................................... 108 
7. Sample  size and statistical power calculations  ......................................................................... 108 
a. Sample size  ......................................................................................................................... 108 
b. Statistical pow er calculations  .............................................................................................. 109 
8. Data Safety & Monitoring Board (DSMB)  .............................................................................. 109 
9. Stoppi[INVESTIGATOR_1869]  ........................................................................................................................ 109 
10. Timing of analysis and adjustment of significance level  .......................................................... 110 
11. Personnel  ................................................................................................................................ 110 
 
 
   
 
    
 
   
 
   
The RETAIN Study: Protocol and Statistical Analysis Plan  
 
8 
 Protocol  Summary  
Title  The Randomized Evaluation of Trial Acceptability by [CONTACT_111505]  (RETAIN) Study   
Short  Title  The RETAIN Study  
NCT #  [STUDY_ID_REMOVED]  
Principal  Investigator  [INVESTIGATOR_73808] D. Halpern, MD, PhD  
Design  This study is a 3 -arm prospective randomized control led trial nested within three 
parent trials . 
Objectives  Aim I:  To determine if the ethical concerns  (i.e., undue and unjust inducement)  with 
incentives for research participation actually manifest.  
Aim II: To assess the possible scientific and ethical benefits of financial incentives for 
RCT participation.  
Aim III: To evaluate the cost- effectiveness of using financial incentives to increase 
RCT enrollment rates.  
This study will provide the first -ever tests of a broad range of intended and 
unintended consequences of real research incentives, thereby [CONTACT_111506].  
 
 Trial Duration  44 months  
 Parent Trials and 
Participating Sites  • Phase III Randomized Trial Comparing Overall Survival After Photon Versus 
Proton Chemoradiotherapy for Inoperable Stage II -IIIB Non -Small Cell Lung 
Cancer, or RTOG 1308  ([STUDY_ID_REMOVED]). Sites: University of Pennsylvania, 
[LOCATION_005] General Hospi[INVESTIGATOR_307], Washington University, St. Louis, and the 
University of [LOCATION_007] at  MD Anderson Cancer Center.  (N.B. this was the first 
parent trial with which RETAIN partnered, but this partnership ended due to 
insurmountable accrual barriers in the parent RTOG 1308 trial due to  
insurance denial of proton therapy . Thus, this collaboration ended after 
only 5 patients were enrolled. We report this history in our original protocol and changes to the protocol ).  
 
• Behavioral Activation and Varenicline for Smoking Cessation in Depresse d 
Smokers Study, or BASC  (NCT 02378714). Sites: University of Pennsylvania and 
Northwestern University.  
 
           
           Sample Size 576 in RETAIN in association with each parent trial (RTOG 1308, BASC, and MOVE 
IT) 
The RETAIN Study: Protocol and Statistical Analysis Plan  
 
9 
 Target Population     Patients eligible for the parent trials RTOG 1308, BASC, and MOVE IT:  
• Adults age 18 years or older with h istologically or cytologically proven 
diagnosis of non -small cell lung cancer (stage II -IIIB) (RTOG 1308)  
• Adults age 18 years or older who are daily smokers with current or lifetime 
major depressive disorder without psychotic features (BASC)  
• Adults age 18 years or older who are admitted for in patient care to the 
Hospi[INVESTIGATOR_71971] (HUP) on medicine or oncology floors  (MOVE IT).  
Eligibility  • Eligible for parent trial  
• 18 years or older  
• No prior knowledge of specific incentives  or randomization  used for  RETAIN  trial 
(RTOG  1308 and BASC trials)  
• Speaks English  
  Randomization  
 Participants will be randomized to the 3 experimental arms ( low-, middle -, and 
high -level incentive ) in equal, 33.3% probabilities. A Penn analyst will implement 
block randomization stratified by [CONTACT_111507]  (RTOG 1308) , 
University of Pennsylvania (Penn), MD Anderson Cancer Center, [LOCATION_005] 
General Hospi[INVESTIGATOR_307] (MGH), and Washington  University, St. Louis ; by [CONTACT_3725] (BASC) at 
the University of Pennsylvania (Penn) and (Northwestern); and finally by [CONTACT_111508] (MOVE IT) at the Hospi[INVESTIGATOR_71971].  
Intervention  The intervention is the randomized incentive amount ( low-, middle -, and high -
level incentive) to be described during the parent trial consent process, including 
on the consent forms.  
Outcomes  Primary Outcome: The proportion of people assigned to each incentive amount 
who  consent to partic ipate in the parent RCT s. 
Secondary Outcomes: Attitudes towards research; patient- reported motivations 
for participation; attention to informed consent document; perceived risks of research; therapeutic misconceptions; perceptions of influence or coercion; understanding of research study ; retention th rough the end of treatment 
sessions.  
 
 Analyses for primary 
aims  We will assess bivariate relationships of incentives with the primary and 
secondary outcomes using t -tests or Wilcoxon rank -sum tests for normally and 
non-normally distributed continuous variables, and chi- square tests for 
comparisons of proportions. To examine hypothesized statistical interactions, 
we will use logistic, linear, or quantile regression, as appropriate based on 
outcome parameterizations and distributions. For all outcomes ot her than tests 
for undue or unjust inducement, we will adjust significance levels for multiple 
comparisons using the Holm method.  
  
  
 
 
 
The RETAIN Study: Protocol and Statistical Analysis Plan  
 
[ADDRESS_124141] common  and conceptually sound1,2 ethical concerns with incentives for research participation 
are that they may (1) represent undue inducements by [CONTACT_111509]’ perceptions of research risks, 
thereby [CONTACT_111510]3-5; or (2) represent unjust inducements by [CONTACT_111511]. N either  of these concerns has been shown to manifest in 
studies using hypothetical incentives for participating in hypothetical RCTs .6-[ADDRESS_124142] a randomized trial of 3 real incentives to participate in three parent randomized clinical 
trials (RCTs).  Following clinicians’ and research staff’s  preliminary  determination of patients’ eligibility in 
the parent RCT, we will assess patients’ research attitudes, demographic characteristics, perce ived 
research risks, time spent reviewing informed consent documents, ability to distinguish research from 
individualized patient care, and comprehension of key trial features. These quantitative assessments will be supplemented by [CONTACT_31576] -structured intervie ws for a selected group of participants that more deeply 
explore patients’ motivations for participating in trials, and the relative influence of incentives on those choices.  
After patients make a decision  about parent trial enrollment, we will debrief patients consenting to the 
parent trial about the random assignment of the incentives. The study will have adequate power to rule out between incentive size and risk perception (i.e., undue inducement) and between incentive size and income or economic well-b eing (i.e., unjust inducement) , using formal “non -inferiority” tests, 
interactions . We also will explore potential benefits of incentives, such as the possibilities that incentives 
improve informed consent by [CONTACT_111512], and that they expedite recruitment enough to b e cost -saving on balance.  
2. Background and Significance  
 
Recruitment problems often cause randomized clinical trials (RCTs) to fail or accrue excess costs  
 
The concomitant problems of under -enroll ment and selective enrollment in randomized clinical trials 
have long plagued efforts to evaluate new and existing medical interventions. 9-13 For example, a recent 
Institute of Medicine report found that 40% of cancer RCTs are never completed and published.14 Under -
enrollment occurs when too few research participants are enrolled to provide adequate statistical power 
to answer the study’s primary research question. Because under -enrollment yields unacceptably high 
probabilities for type II (false negative) errors, these problems reduce the RCT’s ability to answer the 
research question, thereby [CONTACT_111513]’s scientific value and hence, ethics.15,16    Selective 
enrollment occurs when certain subgroups within the target population enroll in proportions greater or 
less than their representation in that population. By [CONTACT_111514]’s results, this problem also curtails scientific value. 
17 
The RETAIN Study: Protocol and Statistical Analysis Plan  
 
11 
 These problems typi[INVESTIGATOR_111449], which has 
been called “the most difficult and challenging  aspect of clinical trials.18” Even when investigators enroll 
an adequate number of participants,  they rarely do so on schedule,13,19,[ADDRESS_124143] costs 
of conducting clinical trials, requiring an average of 13 hours and $[ADDRESS_124144] that financial incentives can increase study enrollment, and that larger incentives are more effective than are 
smaller ones.
6,7,33  
If financial incentives do indeed increase the enrollment fraction – the number of patients enrolled 
among all patients recruited – they could enhance considerably the scientific value and validity of the 
research by [CONTACT_111515] (i.e., statistical power) of RCTs. Further, because prior s tudies by 
[CONTACT_2296]7,8,[ADDRESS_124145] often -cited concern with paying people to participate in research is that incentives 
represent undue inducements – that is, they might alter peoples’ perceptions of the risks associated with 
research participation, thereby [CONTACT_111510]. 3-5,36 -42 In the face of monetary offers, 
particularly those that are large and immediate, people may overlook or underestimate a study’s risks, 
and hence consent to participate against their own better judgment. Importantly, an inducement is not undue if it merely encourages people to do things they would not do for free.
36,37,39,[ADDRESS_124146] inducements – that is, 
incentives could encourage enrollment preferentially among less -wealthy persons. Such differences in the 
effects of pa yments may be unjust if they create a system in which the burdens of research participants 
are borne preferentially by [CONTACT_111516], whereas the knowledge gained from the research would benefit all (or worse, benefit the rich preferentially).
43-[ADDRESS_124147] despi[INVESTIGATOR_111450] -
advantaged persons commonly incur risks for the be nefit of others (e.g., military service, coal mining), 
1,44,46and that larger payments – rather than none – may be needed to counter concerns regarding 
exploitation.44 Thus, to address this controversial matter requires definitive evidence of whether or how 
payment s differentially motivate participation among persons with different incomes or financial needs.  
The RETAIN Study: Protocol and Statistical Analysis Plan  
 
[ADDRESS_124148] changed the 
core question from whether p articipants should be paid to how much is fair.50 Yet the 2 core concerns 
noted above  continue to engender inconsistent policies for regulating incentives by [CONTACT_111517] (IRBs) and funding agencies.2,[ADDRESS_124149] effectiveness of plausible incentive sizes.   
3. Objectives  
a. Aims  
 
Aim I:  The prim ary aim of the RETAIN  trial is to determine if the ethical concerns with incentives for 
research participation actually manifest.  
By [CONTACT_111518] ( see Section 4 . Study Organization ) 
to low-, mid dle-, and high -level incentives  for enrolling, and using our established  methods for measuring 
the unintended consequences  of incentives for participation1,7,8,51, we will conclusively determine how 
incentives influence perceptions of research risks, and  the proportion of economically disadvantaged 
patients who enroll.   
 
Aim II: The  secondary aim of the RETAIN  trial is to assess the possible scientific and ethical benefits of 
financial incentives for RCT participation.  
The potential benefits of incentives also are grounded  more in theory than in evidence. We will 
empi[INVESTIGATOR_111451] 3 potential benefits, testing whether incentives (1) increase the enrollment rate, 
thereby [CONTACT_111519]’s efficiency; (2) increase participants’ attention to risk information and 
their understanding of the research study, thereby [CONTACT_111520]; and ( 3) 
reduce the rate of “therapeutic misconceptions,” defined as patients’ failures to appreciate how the goals 
and processes of research differ from those of c linical care.  
 
Aim III:   The third  aim of the RETAIN  trial is to evaluate the cost -effectiveness of using financial incentives 
to increase RCT enrollment rates.  
To inform the use or nonuse of incentives requires not only that we understand their scientific and ethical 
The RETAIN Study: Protocol and Statistical Analysis Plan  
 
13 
 pros and cons, but also their economic costs. To further guide investigators’ and funders’ decisions 
regarding incentive use, we will assess the inc remental costs relative to the incremental time saved if an 
otherwise identical RCT was conducted with versus without financial incentives.   
b. Primary Outcome Variable  
 
The primary outcome is the proportion of people assigned to each incentive amount that consent to 
participate in the  three parent R CTs (see Section 4 . Study Organization).   
c. Secondary Outcome Variable s 
 
1. Attitudes towards research: Attitudes towards research will be measured using the  
Research Attitudes Questionnaire -7 (RAQ -7).52 The RAQ has high internal consistency and 
factorial validity.53,54 We will measure the RAQ prior to disclosure of incentives in order to 1) 
assess patients’ broad r easons to participate in research or not without being biased by 
[CONTACT_111521] 2) assess whether the hypothesized relationship between RAQ score and the odds of enrolling is modified by [CONTACT_111522]. The presence of such effect 
modification wo uld suggest that incentives represent undue inducements.  
2.  Attention to the informed consent document: Attending more carefully to informed 
consent documents may promote informed choice. 
55 Visual focus has been established as a 
measure of attention in several settings, and has been associated with peoples’ 
choices56,57and subsequent recall. 58 We will assess the  amount of time patients spend 
reading each part of the  parent trial consent form by [CONTACT_111523] a  “survey” 
in REDCap. The data extract will include the time –  to the second –  at which the participant 
moved to another section through a timestamp.   The primary measure of this assessment 
will be time spent on the risk section; the secondary measure will be total time spent on the consent form.  
3. Perceived risks of the research: Perceived risks of the research will be measured by [CONTACT_941] 9 -
item “compared riskiness” scale, which assesses perceptions of research risk .
8   
4. Incidence of therapeutic misconceptions: It has been hypothesized that the use of financial 
incentives could reduce therapeutic misconceptions, and thereby [CONTACT_111524] -making.  [ADDRESS_124150]. Scott 
Kim. 59-61  
5. Understanding of the trial:  In preliminary work, we have shown that research incentives 
may encourage potential participants to spend more time learning about study 
elements.7,27 To assess whether increased attention translates into improved understanding 
The RETAIN Study: Protocol and Statistical Analysis Plan  
 
14 
 of the trial, w e will use a 6 -item Trial Elements Quiz, featuring core elements of the parent 
trial’s consent form.   
6. Perceptions of influence or coercion: To measure general perception of coercion and 
voluntariness of research participation, we will use the five -item Perceived Coercion Scale 
of the MacArthur Admission Experience Survey62. The true/false scale is tailored to measure 
patients’ perceptions of coercion in the inpatient psychiatric treatment admission process; we have edited the wording to make it relevant to participation in the parent trials .
  
7.  Retention through  the end of treatment sessions: To assess the impact of incentives on 
retention status in the protocol, we will disburse payment in two installments-  one as soon as 
possible after debriefing and one during the patient’s last week of treatment therapy  or study 
intervention . The denominator for analyses of this outcome will be all those who received the 
first payment . We will assess whether patients completed their treatment, and if not, reasons 
for non -completion.  
Please see  Section 8. f.  Administration of S urvey Instruments for  additional information on the  Study  
Instruments used to measure outcomes  for the RETAIN  trial.  
4. Study Organization  
a. RETAIN Infrastructure  
 
The RETAIN study infrastructure is supported by [CONTACT_111525] : 
1) The Phase III Randomized Trial Comparing Overall Survival After Photon Versus Proton 
Chemoradiotherapy for Inoperable Stage II -IIIB Non -Small C ell Lung Cancer, or RTOG 1308 , a 
two-arm trial comparing conventional, intensity -modulated radiation therapy (IMRT) with 
proton -beam therapy (PBT) for the treatment of non -small- cell lung cancer (NSCLC). The 
primary outcome of this trial is overall survival ([STUDY_ID_REMOVED]).  
 
2) The Behavioral Activation and Varenicline for Smoking Cessation in De pressed Smokers Study, 
or BASC , which tests two behavioral interventions in combination with Chantix in a population 
of daily smokers with current or lifetime  major depressive disorder  (BASC ). The primary 
outcome of this trial is point -prevalence abstinence post target quit date (NCT 02378714).    
 
3) The Mobility, Outcomes, and Validated Experience s Incentive Trial, or MOVE IT , which targets 
adults admitted for inpatient care on medicine or oncology floors on [ADDRESS_124151] of a hospi[INVESTIGATOR_307] -
implemented mobility protocol for general medical and cancer patients using wearable 
technology.  The primary outcome is the change in mean daily step count from the baselin e 
period (week [ADDRESS_124152] -discharge) to the intervention period (weeks [ADDRESS_124153] -discharge)  (NCT 
n/a). 
The RETAIN Study: Protocol and Statistical Analysis Plan  
 
[ADDRESS_124154]. Scott Hal pern (PI) is Associate Professor of Medicine, Epi[INVESTIGATOR_623], and Medical Ethics & Health Policy 
at Penn, and Deputy Director of the Center for Health Incentives and Behavioral Economics (CHIBE) at the Leonard Davis Institute of Health Economics  and Director  of the Palliative and Advanced Illness Research 
(PAIR) Center . He has considerable expertise in the design, ethics, and recruitment barriers of clinical trials, 
in leading RCTs of financial incentives to modify health behaviors, and in the ethics of using  behavioral 
economic approaches, including incentives, to modify health -related decisions.  
[CONTACT_111597] (Co -I) is Director of the CHIBE and PENN -CMU Roybal P30 Center on Behavioral Economics 
and Health. He has successfully completed numerous NIH-funded RCTs of financial incentives to modify 
health -related behaviors.  
[CONTACT_111598] (Co -I), Professor of Medicine and Medical Ethics & Health Policy, is one of the nation’s 
leading scholars on patient capacity to consent to research and decisions to enr oll in trials. He has extensive 
experience using many of the instruments to be employed in this study, and is an expert in interpreting the data they produce.  
[CONTACT_111599] (Co -I) is Associate Professor of Family Medicine and Co -Director of Penn’s Mixe d Methods 
Research Lab. She has great expertise in the use of qualitative methods in medical research and will work closely with [CONTACT_32649] to oversee the conduct of semi- structured interviews, once implemented, to assess 
patients’ motivations for participating in the RCT.  
[CONTACT_111600] (Co -I) is Professor of Medicine and Executive Director of the Leonard Davis Institute of 
Health Economics. He is a leading authority on economic analyses within RCTs, and will guide our analysis of the cost- effectivenes s of incentives for RCT enrollment.  
[CONTACT_111601] -Shields (Co -I), Assistant Professor of Biostatistics in Biostatistics and Epi[INVESTIGATOR_111452], will be the principal biostatistician for this RCT. She has significant  experti se in 
clinical trials and longitudinal data analysis.  
Site Principal Investigators  
RTOG [ADDRESS_124155]. Samuel Swisher -McClure  (Co-I), Assistant Professor of Radiation Oncology at the Hospi[INVESTIGATOR_71972], has clinical expertise in the multidisciplinary management of patients with 
thoracic and head and neck malignancies and  leads as Site Principal Investigator [INVESTIGATOR_111453], RTOG 
1308, at the Perelman Center for Advanced Medicine. [CONTACT_111602] -McClure will provide ongoing support in  
The RETAIN Study: Protocol and Statistical Analysis Plan  
 
[ADDRESS_124156]. Zhongxing Liao (Co -I), Professor and  Clinical Medical Director of the Department of Radiation Oncology 
at the University of [LOCATION_007] MD Anderson Cancer Center, is the National  Principal Investigator [INVESTIGATOR_111454] [ADDRESS_124157]. Jeffrey Bradley (Co -I), Lee King Professor of Radiation Oncology at Washington University School of 
Medicine and the Alvin J Siteman Comprehensive Cancer Center ,  is a Site Principal Investiga tor on RTOG 
1308. [CONTACT_111603]  also serves as Clinical Director of the Kling Proton Therapy Center and as Chief of the 
Radiation Oncology Thoracic Service at Washington University, St. Louis.  
[CONTACT_111604] (Co -I), Professor of Radiation Oncology and Direct or of Thoracic Radiation Oncology at 
[LOCATION_005] General Hospi[INVESTIGATOR_111455], is a Site Principal Investigator [INVESTIGATOR_111456] [ADDRESS_124158]. Brian Hitsman  (Co-I), Associate Professor of Preventive Medicine and Psychiatry and Behavioral Sciences 
at Northwestern University, is the Principal Investigator [INVESTIGATOR_111457] -funded parent study Behavioral 
Activation and Varenicline for Smoking Cessation in Depressed Smokers Study  (BASC ). Dr. HItsman will lead 
BASC  parent trial research staff at the Northwestern site in RETAIN recruitment efforts.    
[CONTACT_111605] (Co -I), Associate Professor of Psychology in Psychiatry at the University of Pennsylvania is 
Site Principal Investigator [INVESTIGATOR_111458] -funded parent study  Behavioral Activation and Varenicline for 
Smoking Cessation in Depressed Smokers Study  (BASC ). [CONTACT_111606] will lead BASC  parent trial research staff 
at the Penn site in RETAIN recruitment efforts. Together  with Co -I Hitsman, [CONTACT_111606] will work with [CONTACT_32650] to address any issues that arise with recruitment, study execution, or data monitoring.  
MOVE IT  
[CONTACT_111607] (Co-I), Chief of the Section of Hospi[INVESTIGATOR_111459], is the Principal Investigator [INVESTIGATOR_111460], Out comes, and Validated Experiences Incentive 
Trial, or MOVE IT. [CONTACT_111608] will oversee recruitment in the inpatient hospi[INVESTIGATOR_111461] -
RETAIN partnership, in collaboration with Drs. Patel (Co -I) and Halpern.  
[CONTACT_111609]   (Co-I) is an Assi stant Professor of Medicine and Health Care Management at the Perelman 
School of Medicine and The Wharton School at the University of Pennsylvania is the Co -Investigator for the 
Mobility, Outcomes, and Validated Experiences Incentive Trial, or MOVE IT .   
 
c. Participating Parent Trial Sites 
Parent Trial  Site Name  [CONTACT_111594] 1308  The Hospi[INVESTIGATOR_111462], PA  [ZIP_CODE]  
The RETAIN Study: Protocol and Statistical Analysis Plan  
 
17 
  
The RETAIN  trial will be conducted at  four  sites participating in the RTOG 1308 parent trial , the  Hospi[INVESTIGATOR_111463] (Penn), MD Anderson Cancer Center, [LOCATION_005] General Hospi[INVESTIGATOR_307] (MGH), 
and Washington University, St. Louis ; two sites participating in the BASC  parent trial, Northwestern 
University and the University of Pennsylvania; and one site participation in the MOVE IT parent trial, the  
Hospi[INVESTIGATOR_111464].  These institutions are imbued with substan tial research 
infrastructures and offer close proximity of site PIs to the clinics from which patients  will be recruited. Each 
parent trial supports research staff; in collaboration with the Site PIs, the parent trial research staff  will 
carry out the prot ocol at their respective institutions.      [LOCATION_005] General Hospi[INVESTIGATOR_111465], MA  [ADDRESS_124159]. Louis, MO  [ZIP_CODE]  
University  of [LOCATION_007] MD Anderson Cancer Center  Houston, TX  [ZIP_CODE]  
BASC  Northwestern University  Chicago, IL [ZIP_CODE]  
The University of Pennsylvania  Philadelphia, PA  [ZIP_CODE]  
MOVE IT   The Hospi[INVESTIGATOR_111462], PA  [ZIP_CODE]  
The RETAIN Study: Protocol and Statistical Analysis Plan  
 
[ADDRESS_124160] ive randomized controlled trial nested within three real randomized controlled trials.   
a. RTOG 1308  Schema  
 
 

The RETAIN Study: Protocol and Statistical Analysis Plan  
 
19 
 b. BASC  Schema  
 
 
 

The RETAIN Study: Protocol and Statistical Analysis Plan  
 
20 
 c. MOVE IT Schema  
 

 
 
 
21 
 d. Key Study Design Elements across Parent Trials   
 
Key elements in study design across the three parent trials  are highlighted in the table and figure  below.  
 RTOG 1308  BASC  MOVE IT  
Is there a separate step 
to screen for RETAIN-
specific eligibility?  
 
 
 
Please see Section 8.b.  
Eligibility.  
 Yes 
 Patients will be probed for 
prior  knowledge of 
incentive randomization, equalization, or the maximum amount offered 
under RETAIN.  
 Yes 
 
Patients will be probed for 
prior  knowledge of 
incentive randomization, equalization, or the maximum amount offered 
under RETAIN.  
 No 
 
 
Do patients actively 
consent to the RETAIN trial?  
   
Please see Sections 8.d. 
and 8.e.  Informed 
Consent.  
 Yes 
 Research staff first solicit  
consent for a “research attitudes study” (RETAIN consent) and then solicit  
consent for the parent study.  
 No 
 A waiver of consent for 
RETAIN has been approved 
by [CONTACT_1201].  No 
 A waiver of consent for 
RETAIN has been approved 
by [CONTACT_1201].  
Can anyone enroll in 
the parent trial without enrolling in RETAIN?  
 Yes, if they decline the 
Research Attitudes consent or screen ineli gible 
specifically for RETAIN.  Yes, if they screen 
ineligible specifically for RETAIN  No 
Incentive for parent 
trial subjects not 
enrolled in RETAIN  
 
Please see Section 6.d.  
Subject Remuneration.  
 $0  $200  Not applicable  
Incentive levels  
 
Please see Section 7 . 
Randomization . Low:  $0  
Middle:  $400  
High:  $1,200  Low:  $0  
Middle:  $200  
High:  $500  Low:  $0 
Middle:  $100  
High:  $[ADDRESS_124161] Remuneration.  $1,200 in two $600 
installments  
 
  
 
 $300 in two $150 
installments , plus up to 
$200 from individual 
session/travel payments.1 $300 in two $150 
installments  
   
 
  
                                                           
1 The high- level incentive arm in the BASC -RETAIN study is $500. This amount accounts for a $200 payment for time, effort, and 
travel pai d for by [CONTACT_111526], which existed prior to partnering with the RETAIN  study , as well as $[ADDRESS_124162] 2016 . The trial is slated to conclude June 30, 2020, following the 
development of a manuscript and dissemination of our findings.  
i. RTOG 1308 
 
RETAIN procedures will be  conducted over one to three visits across one day to two weeks, depending 
on the sequence of eligibility determination and treatment planning conducted by [CONTACT_111527]  1308 research 
staff at each site. Study participants will be asked to spend approximately 30 -75 minutes of their time to 
complete the questionnaires and consent processes for both the RETAIN trial and the parent trial (see 
Section 8.f.  Administration of Survey Instruments) . Following consent, participants will be debriefed and 
compensation will be arranged  at the next in -person appointment . We anticipate that the debriefing 
and payment process will take approximately [ADDRESS_124163]’s participation time in the study will exceed two hours.  
ii. BASC  
 
RETAIN procedures will  be conducted over two phone calls and one in -person visit across one day to 
three weeks, depending on the intake scheduling capacity of the Penn and  Northwestern clinics. RETAIN 
procedures will commence during the initial pre -screening eligibility assessment for BASC  participants , 
which takes place before participants’ first in -person or “intake” visit with BASC  research staff. This 
phone assessment , which  reduces the likelihood that BASC  participants will attend an intake session 
only to learn that they are ineligible , is a pre -screening encounter  during which participants  first learn 
basic details of the BASC  trial. If eligible for RETAIN, they will be randomized  and complete the first set 
of RETAIN assessments over the phone.  RETAIN assessments will take 10 additional minutes during the 
initial phone eligibility call  (see Section 8.f.  Administration of Survey  Instruments ).   
Participants who pass the BASC  pre-screening on the phone  will schedule a baseline intake visit. During 
the baseline intake visit, RETAIN assessments , including the BASC  consent process,  will constitute [ADDRESS_124164] visit once enrolled on the study ; during this call, all RETAIN -randomized, BASC -consented patients 
will be debriefed  and learn of the payment procedures. The debriefing process will take [ADDRESS_124165]’s participation time in the 
study will exceed two hours.  
iii. MOVE IT  
 
RETAIN proc edures will commence during clinical research coordinators’ initial encounter with patients  
 
 
 
[ADDRESS_124166]. The cli nical research coordinator will administer all RETAIN assessments in one  
encounter  (see Section 8.f.  Administration  of Survey Instruments ).  Study participants will spend 
approximately [ADDRESS_124167]’s participation time in the study will exceed 
two hours.  
6. Subject Recruitment  
 
Recruitment for t he RETAIN study is intricately linked to recruitment for the parent RCT s. No 
recruitment efforts outside the parent trials’ efforts  will occur. Specific measures will be taken to ensure 
that patients who are exposed to RETAIN procedures by [CONTACT_72683] -of-mouth (R TOG 1308 and BASC ) or 
during their inpatient stay (MOVE IT) are screened out or not approached for the RETAIN study.   
a. Accrual  
 
During the 44 -month period of the  trial, we plan to enroll 576 patients in RETAIN in association with 
each parent  trial. If this  goal is achieved, there would be a total of roughly 1,778 patients in RETAIN 
overall, but RETAIN data associated with each of the 3 parent trials will be analyzed separately. Within 
each parent trial, we anticipate that 50% of RETAIN patients (288 of 576)  will choose to enroll in the 
parent trial. However, we recognize that the total sample sizes and consent rates may vary across the 3 
parent trials associated with RETAIN.   
b. Key inclusion criteria  
 
The eligibility criteria are:  
 
1) Eligible for parent trial  
2) 18 years or older  
3) Speaks English  
c. Key exclusion criteria  
 
In the RTOG [ADDRESS_124168] remuneration  
i. RTOG 1308 
 
Participants who only consent to participate in  RETAIN study  (see Section 8. d. Informed Consent  for 
RETAIN in RTOG 1308 ) will not receive any payment. Participants who consent to participate in the 
RETAIN study and the parent trial RTOG 1308 will receive a two -installment payment amounting to a  
total of $1,[ADDRESS_124169] 
payment ($600) as soon as possible after debriefing. They will receive the second payment ($600) 
during their final week of treatment therapy for the RTOG 1308 trial. Patients who are taken off the 
RTOG 1308 study for medical reasons will receive full compensation. If patients withdraw from the 
study  for personal reasons, they will not receive the second payment.  
ii. BASC  
 
Prospective participants who are not eligible, randomized, and enrolled in RETAIN but consent to the 
BASC  parent trial receive $200 in time, effort, and travel payments. Participants who are eligible, 
randomized, and enrolled in  RETAIN and consent to the BASC  parent trial will receive a total of $500 
(see Section 8.e.  Informed Consent for RETAIN in BASC  and MOVE IT  and Section 8.g.  Parent Trial 
Informed Consent ); $300 of this payment derives from  the RETAIN incentive payment, while $[ADDRESS_124170] payment ($150) as soon as possible after debriefing, during their first in -person visit on trial (Pre -Quit 1). They will receive the second 
payment ($150) during their final week of treatment for the BASC  trial (Week 27). Participants who  are 
taken off the BASC  study for medical reasons will receive full compensation. If participants  withdraw 
from the study for personal reasons, they will not receive the second payment . 
iii. MOVE IT  
 
Patients who are not eligible for MOVE IT will not be paid. Participants who are eligible for MOVE IT , 
enrolled in RETAIN,  and consent to the study will receive the payment in two installments  (see Sect ion 
8.e. Informed Consent for RETAIN in BASC  and MOVE IT ). They will receive the first payment ($150) as 
soon as possible after debriefing; they will receive  the second p ayment ($150) during their final week of 
participation (week 13). Participants who are taken off the MOVE IT study for medical reasons will 
receive full compensation. If patients withdraw from the study for personal reasons, they will not 
rece ive the second payment.  
e. Payment Equalization  
 
During the debriefing session, the parent trial staff will explain that all RETAIN - and parent trial- enrolled  
participants will receive the full high -level incentive payment  ($1,2 00 in RTOG 1308 , $300 in BASC  (see 
 
 
 
27 
 Section 6.d.iii) , and $300 in MOVE IT) in two installments . Such payment equalization is necessary 
because it promotes fairness by [CONTACT_111528].  
7. Randomization  
a. Groups  
 
Subjec ts enrolled in  RETAIN  will be randomized into three groups. Depending on which group they’ve 
been assigned, subjects will be presented with  one of three parent trial consent forms  in both electronic 
and paper formats (see Section 8 Study Procedures) . The parent trial co nsent forms will display three 
different incentive amounts ( low-, mid dle-, or high -level  incentive ). Consent 1 ( low-level  incentive arm ) 
will include a paragraph on the first page that will briefly state what the study is about and indicate to 
patients that participation in the study is voluntary and patients will not be paid if they choose to participate. The consent form will indicate tha t participants will not be paid  under the standard section , 
“Will I be paid for taking part in this study?” Consent s 2 (middle -level  incentive arm)  and 3 (high -level 
incentive arm)  will include a paragraph on the first page that will briefly state what the  study is about 
and indicate that participation is voluntary and patients will be paid the incentive (mid dle- or high -level)  
if they choose to participate. The consent form will also include payment information under the standard sec tion, “Will I be paid for taking part in this study?”  that describes  the level. Consents [ADDRESS_124171] section (RTOG 1308 and BASC  trials).  During debriefing , all participants 
enrolled in RETAIN and their respective parent trials will learn of their as signment to one of three 
groups . 
b. Assignment  
 
Participants will be randomized to the 3 experimental arms (low -, mid dle-, and high -level incentive ) in 
equal, 33.3%  probabilities. A Penn analyst will implement block randomization stratified by [CONTACT_111529] 1 308 parent trial; stratified by [CONTACT_111530] ; and 
stratified by  [CONTACT_111531]. The trial’s primary statistician  on the 
Penn research staff will provide a  block randomization scheme for each provider  (RTOG 1308) or clinical 
research coordinator (MOVE IT)  and will upload a CSV file to the REDCap randomization module . He/she 
will also  provide a block randomization scheme for each site for the  Access Data Management System 
(BASC ) (see Section 10 . Data Management –  BASC ). The parent trial research staff will enter the 
provider  (RTOG 1308) or clinical research coordinator (MOVE IT)  inform ation into the REDCap software 
through an initialization step and will immediately receive the randomization assignment for that 
participant. This will allow them to message to the participant the appropriate incentive level for 
participation in the parent  trial, and present the correct paper consent  based on their arm assignment  
(see Sections 8.g.  Parent Trial Informed Consent) .  
 
 
 
28 
 i. RTOG 1308 
 
Randomization and group assignment occurs after the economic well -being, demographic, and 
attitudes towards biomedical research , prior experience with research studies questions are assessed 
(see Section 8.f.1  Administration of Survey Instruments –  RTOG 1308 ). Therefore, the parent trial 
research staff will not know group ass ignment when patients are approached and completing initial 
assessments. Once randomization occurs, by [CONTACT_100827], the research nurse/staff will know group 
assignment so that the correct electronic RTOG parent trial consent form ($0, $400, $1,200)  can be 
viewed.  
ii. BASC  
 
Randomization and group a ssignment occurs after pre -screen ing data are collected and RETAIN 
eligibility probes are administered on the eligibility pre -screening call for the BASC  parent trial (see 
Section 8.f .2 Administration of Survey Instruments – BASC ). Research staff will know  group assignment 
when patients are first introduced to the BASC  trial on the phone in order to message the assigned 
payment ($0, $200, $500) for the participant. Participants who are deemed preliminarily eligible will schedule an intake session, where the y will view the electronic BASC  parent trial c onsent form ($0, 
$200, or $500) and receive a paper copy of the form with respective incentive information.  
iii. MOVE IT  
 
Randomiza tion and group assignment occur  after MOVE IT screenin g steps  (see Section  8.f.3 
Administration of Survey Instruments –  MOVE IT ) following clinical research coordinators’ brief 
introduction to the study upon entering patients’ hospi[INVESTIGATOR_39223]. Clinical research coordinators will 
randomize patients and  know the group assignment  as they  complete the recruitment script and assess 
patients’ interest in l earning about the MOVE IT trial. Assignment occurs prior to registering the patient 
in the Way to Health  platform used for survey administration . 
8. Study Procedures  
 
a. Screening  
 
 In the RTOG [ADDRESS_124172] before the patient arrives for his/her  radiation oncology  consultation, or within several days 
following the consultation . Patients will be screened for RETAIN eligibility immediately after watch the 
RTOG [ADDRESS_124173] until labs are 
conducted at the baseline intake session, following participants’ signature [CONTACT_111595]. However, initial eligibility screening on the pre - screen  eligibility  call will enable the BASC  research 
team  to determine which participants may be assessed for RETAIN eligibility.  
In the  MOVE IT study, clinical research coordinators will pre - screen participants for parent trial 
eligibility  prior to  the initial approach on the inpatient wards. However, final eligibility determination 
will take place immediately after coordinators’ initial approach once smartphone ownership and 
patients’ participation status in other physical  activity trials is ascertained.  
 
b. Eligibility  
 
Using methods employed by [CONTACT_976] [INVESTIGATOR_111466],29,30,64 parent trial research staff will use 
prompts to assess participants’ prior knowledge about the RETAIN  study  in the RTOG [ADDRESS_124174] s of the hospi[INVESTIGATOR_307] ; no two patients will be 
approached in the same room at once; and readmitted patients will not be re -approached.  
 
c. Inclusion of Women and Minorities  
   
 No participants will be excluded from study participation based on gender, race, or 
ethnicity. We expect that enrollment of participants from The University of Pennsylvania 
Perelman Center for Advanced Medicine,  Northwestern University, the University of [LOCATION_007] 
MD An derson Cancer Center, Washington University and [LOCATION_005] General Hospi[INVESTIGATOR_111467]-patient clinics  and the Hospi[INVESTIGATOR_111468], race, and ethnicity. These populations are also reflective of the broader populations of the Philadelphia,  Chicago,  Houston, St. Louis, and [LOCATION_011] 
metropolitan areas.  
 
d. Informed Consent  for RETAIN in RTOG 1308  
 
In the RTOG 1308 study, a ll RETAIN -related  procedures and processes for the RETAIN  study will be 
covered in an initial consent process except patients will not be informed that they will be randomly 
assigned to different incentives ($0, $400, $1,200) for p articipating in the parent RCT. This is necessary 
because it would be impossible to test the effect of different incentives on study participation if participants were aware of this randomization. Please see the  Section s 8.h -8.j Debriefing  for details on 
 
 
 
30 
 how this omission will be handled.   
 
For all patients without prior knowledge of the incentives of any size  or payment equalizati on (see 
Section  8.b. Eligibility ), the parent trial research staff  will solicit consent to participate in a “study of 
attitudes about research on different forms of radiation for non -small cell lung cancer.” By [CONTACT_111532], patients will authorize the  use of basic demographic data and  agree 
to complete questionnaires that measure the secondary outcomes of the incentives trial . 
 
Of note, patients who decline participation in this study will be given an opportunity to consent in the 
parent trial, RTOG 1308.  
 
e. Informed Consent for RETAIN i n BASC  and MOVE IT  
 
The sole informed consent processes used in both BASC  and MOVE IT will be for the parent trials  (see 
Section 8.g.  Parent Trial Informed Consent) . Randomization and enrollment  to RETAIN in the BASC  and 
MOVE IT studies will be carried out under a Waiver of Informed Consent, approved by [CONTACT_111533].  Thus, research staff will not present a “study of research attitudes” prior to 
randomization. BASC  participants  deemed el igible for BASC  via phone pre -screening and RETAIN MOVE 
IT participants will be randomized immediately after eligibility screening in their  hospi[INVESTIGATOR_60916].   
 
All participants who are randomized and enrolled in  RETAIN and consent to the  BASC  and MOVE IT will 
be debriefed on the randomization of incentives and the purpose of the RETAIN study will be explained  
(see Sections 8.i. and 8.j.  Debriefing in BASC  and MOVE IT) .  
f. Administration of Survey Instruments  
i. RTOG 1308 
 
Consenting pa rticipant s will then complete a series of questionnaires (demographic characteristics, 
income and economic well- being, attitudes towards biomedical research , and p rior experience with 
research studies  questions ) with the parent trial research staff via REDCap  using a tablet device . 
 Once these measures have been completed , participants will be randomized to receive one of three 
different versions of the informed consent form for the parent trial, RTOG 1308, each indicating 
different financial incentive amounts  ($0, $400, or $ 1,200) .  Once the parent trial research staff  has 
received the appropriate randomization, he or she will briefly introduce the informed consent form and 
note whether pa tients are being offered either  $0, $400, or $1,200, depending on random ization, to 
participate in the parent trial. Participants will be presented with their assigned consent forms 
electronically  for review on their own.  Participants will NOT be alerted to their assigned parent trial arm 
(conventional radiotherapy or proton -beam  therapy) at this stage. This step will occur at or before their  
simulation appointment .  
 
 
 
[ADDRESS_124175] been reviewed, but not signed, participants will be asked to complete the 
Compared Riskiness and Therapeutic Misconception tool as well as the trial elements quiz. The parent 
trial research nurse/staff will review the answers to the t rial elements quiz.  Patients’ advancement 
through the consent process will not be contingent on their responses to the quiz;  however, following completion of the quiz, the parent trial research nurse/staff will review the questions that patients 
missed and discuss these portions of the consent until the participant understands the entire consent 
and its detailed procedures. The participant will be encouraged to ask questions about portions they do 
not understand.  
ii. BASC   
 
Procedures for this study will commence during in itial pre-screen ing eligibility assessment via phone for 
the BASC  trial. During this call, all study candidates will complete an initial eligibility assessment with 
research staff members from the clinical site from which they are being recruited (Northwes tern or 
Penn) . Research staff will begin with the BASC  eligibility screen  survey, which includes basic 
demographic questions, as well as questions related to participants’ endorsement of symptoms of 
clinical depression . Once a patient is determined to be p reliminarily eligible for BASC , the research staff 
will ask the RETAIN eligibility prompt to assess for prior knowledge of the specific incentives o r 
randomization used for RETAIN . Participants who do not have prior knowledge of the  RETAIN incentives 
or randomization will be randomized by [CONTACT_111534]’s Data Management System 
(DMS)  (see Section 10.a.3.  Data Collection and Data Confidentiality –  BASC ). Prospective participants 
will then be introduced to BASC  study basics and risks an d informed that if they are determined to be 
eligible for the BASC  study  and participate in the BASC  trial, they will receive $0, $200, or $[ADDRESS_124176] study information regarding session and travel compensation  for the BASC  trial 
without RETAIN messaging. For information on r emuneration in the BASC  trial, see Section 6.d. . These  
participants will not be debriefed or paid the RETAIN incentives.  
 
Before  research staff finalize logistical details on the BASC  study and schedule intake s for tentatively 
eligible patients, they will administer several RETAIN -related questionnaires to assess 1) demographics 
and personal financial well- being, 2) attitudes towards biomedical research, 3) pr ior experience in 
research, and 4) perceptions of research risk . The screener will administer these  surveys via phone 
using CRF forms adopted for the RETAIN trial that will later be s canned into the BASC  trial’s DMS.  
 
Participants who pass the BASC  pre-screening will be scheduled  to attend a 2 -3½ hour Intake session for 
the BASC  trial. During the intake session , BASC  research staff at Penn and Northwestern will read a pre -
BASC  consent script before presenting an electronic image of the BASC  informed consent/ HIPAA forms 
with additional information regarding the RETAIN incentive randomization condition ; this electronic 
 
 
 
32 
 image will be presented via tablet or desktop . By [CONTACT_111535], we will assess the amount of time participants spend reading 
each part of the main trial consent form. Eac h section (e.g., Study Introduction, Procedures by [CONTACT_4838], 
Possible Risks and Discomforts, etc.) will be presented as a survey in REDCap. Time -stamp data collected 
for this REDCap module will be linked by [CONTACT_111536] S ystem  
during candid ates’ telephone pre -screen call (see Section 10 .a.3 Data Collection and Data 
Confidentiality - BASC ). 
 
Once participants finish reading and before signing a paper version of the BASC  trial consent, they will 
complete brief assessments of  perceptions of research risk (administered over the telephone pre-
screen and again at intake  – see Section 9.b.  BASC  Study Calendar). They will also complete assessments 
on perceptions of the difference between research and individualized patient care and  understanding of 
the smoking cessation study via a trial elements quiz. All of these measures will be administered via the 
CRF paper and pencil processes currently used in the BASC  trial. The responses to the quiz will be 
reviewed with participants, durin g which participants’ questions will be answered.   
 
iii. MOVE IT  
 
Clinical research coordinators will identify patients through  electronic health record -based  screening for 
the MOVE IT study  and preliminarily eligible patients will be approached for recruitment  in their 
hospi[INVESTIGATOR_60916] . 
 
Using a recruitment script in  REDCap , clinical research coordinators will describe a study that aims to 
help patients improve their mobility and prevent them from needing to return to the hospi[INVESTIGATOR_307].   The 
REDCap -hosted MOVE IT recruitment script will prompt the clinical research coordinator to assess for 
patient’s eligibility in the MOVE IT study  through two screening questions . Eligible patients will be 
randomized in real time to one of three incentives for participation ($0, $100,  or $300) . The clinical 
research coordinator will finish reading the  recruitment script, indicating  the amount participants will 
be paid for the MOVE IT Trial.  Ineligible patients will not be randomized  or enrolled on the RETAIN trial.  
 For patients  who are interested in learning more about the MOVE IT study, the MOVE IT clinical 
research coordinators will proceed to register the participant in the Way to Health  platform  and 
administer the tools in Way to Health via tablet  (see Section 10.a.3 . Data Management - MOVE IT). The  
patient  will be asked to complete several short  questionnaires : 1) demographics, 2) personal financial 
well- being, 2) attitudes towards biomedical research, and 3) prior  experience in research . 
 
Once the patient has completed aforementioned tools in Way to Health, the clinical research 
coordinator will return to the REDCap database and read  a pre -consent introductio n script  before  
presenting the an electronic image of the MOVE IT informed consent/ HIPAA forms with additional 
information regarding the RETAIN incentive randomization condition. By [CONTACT_111537], we will assess the amount of time 
 
 
 
[ADDRESS_124177] to Health  platform on a tablet . The responses to the q uiz will be reviewed with participants, 
during which participants’ questions will be answered.   
 
g. Parent Trial Informed Consent ( RTOG 1308, BASC , and MOVE IT )  
 
Parent trial research staff will present  the paper consent  in conjunction with their review of any 
questions  generated by [CONTACT_941] p articipant during their review of the  electronic, REDCap -hosted images of 
the consent form . Next , prospective participants will be asked to either provide consent or decline 
participation in the parent trials. The research staff  will then facilitate participants’ completion of the 
final two surveys (perceived coercion and prior persuasion questions) .  All participants –  no matter their 
decision – will be asked to complete these two post- consent surveys.   
 
In the RTOG 1308, p articipants who decline consent will proceed with their treatment under the 
guidance and assistance from their MD outside of the context of this trial.  
 In the BASC  and MOVE IT studies, participants who decline  consent  may se ek participation in other 
trials for smoking cessation or physical activity, respectively.  
  
h.  Debriefing in RTOG 1308  
 
At the participants’ simulation, or dry run/set -up appointment, patients will be informed of their 
treatment randomization. During this appointment , or at the first possible time  to debrief in -person  
following this appointment  (i.e. first treatment visit) , the parent trial research staff will read the 
debriefing script, which will inform the participant of the trial deception and purpose. The parent trial 
research staff will explain that the incentives were randomly assigned. Such debriefing has long been used in studies for which the research questions could not be answered if certain study procedures 
were disclosed up front.  Debriefing increases the moral accountability of the researchers, promotes 
transparency for patients, and fulfills a Federal criterion for using interventions not described during the 
informed consent process. Using the attached script, the parent trial research staff will inform patients 
that: (1) recruitment for the parent RTOG trial included a study of the effects of incentives on 
enrollment and decision making; (2) patients were randomly assigned to receive incentives of $0, $400, 
 
 
 
34 
 or $1,200; (3) patients were not i nformed about the incentives study to avoid bias; (4) patients should 
not disclose their incentives to others to prevent biasing future patients’ enrollment decisions; and (5) 
no further data will be collected as part of the incentives study  after the incentives are disbursed .  They 
will also learn about the payment equalization and informed that they will earn the full $[ADDRESS_124178] signed consent, and 
they are determined to be fully eligible for the BASC  trial. Debriefing will take plac e on the reminder call 
before participants’ first scheduled visit on trial, called “Pre -Quit 1.”  The same processes described in 
Section 8. h. will be  used to inform patients of the RETAIN study procedures and process payment per 
institutional standard.  
j. Debriefing in MOVE IT  
 
Participants will be debrief ed during the same encounter in which they are approached. The same 
processes described in Section 8. h. will be  used to inform patients of the RETAIN study procedures and 
process payment per institutional standard .  
 
k. Deception  
 
We believe debriefing remains an essential element of this RCT in which information regarding the 
random allocation of incentive levels is necessarily withheld during the consent processes. The 
following justifications support the re search team’s use of incomplete disclosure in the RETAIN trial:  
 
The use of incomplete disclosure in this study is grounded in the trial’s status as minimal risk.  
 
The RETAIN  study involves no more than minimal risk to participants for 5 reasons: (1) incentives in the 
amounts we are proposing are given to patient subjects as part of many ongoing or completed trials;35 
(2) the evidence  available to date suggests that t he ethical concerns identified with incentives may not 
arise, (3) we have established robust procedures for monitoring whether those ethical concerns do in fact arise and for stoppi[INVESTIGATOR_111469], (4) the patients would be approached to 
participate in the parent RCT s without the incentive study, and (5) their participation in the RETAIN 
study will not affect which treatment they receive in the parent RCT s. 
 
To the extent that it is avoidable, the use of deception will have no adverse effects on welfare, and all 
adverse effects will be minimized.  
 
 
 
35 
  
Adverse events from the incomplete disclosure of the randomization of participants to different levels 
of incentives will be minimized through the debriefing process. Patients will be debriefed follow ing their 
decision to enroll in the parent trial during the very next appointment at the radiation oncology clinic  
(RTOG 1308); immediately before their first treatment visit ( BASC ); and within the same session as the 
initial approach (MOVE IT) . This debriefing will therefore happen within a few days  (at maximum)  of the 
deception, and will provide participants with full disclosure of the research and with an opportunity to 
withdraw their participation or their data. Patients who decline to participate in the  parent trials will 
not be debriefed. The Principal Investigator [INVESTIGATOR_111470].  
 
Additional oversight will be provided by [CONTACT_716]: (1) a DSMB that will have the flexibility to adjudicate trial continuation or cessation based on a compendium of outcomes data; (2) two advisory boards comprised of experts in relevant disciplines including research ethics and regulatio ns that will 
assist the investigators in addressing any unforeseen ethical and scientific issues during the trial’s conduct.  
 
The value of the study is sufficient to warrant waiving some aspects of the requirement for full 
disclosure in the informed consen t process.  
 
While our study does not provide participants with untrue information and thus does not technically qualify as deception research, it remains necessary for parent trial research staff to withhold information regarding the random assignment of incentive levels during the incentives trial consent process. This RCT will provide important information about the impact of financial incentives on 
enrollment in a research study with therapeutic benefit. Because it is taking place within the context of 
a real RCT and the incentives will be randomly assigned, this will be the first every study to explore how 
financial incentives impact actual decisions made by [CONTACT_111538] a real trial. 
It will inform the practice of paying human  research subjects to participate in studies by [CONTACT_1541] a new 
standard by [CONTACT_111539]. Specifically, the study is designed to inform the conduct of 
future human research subjects by [CONTACT_111540], and whether reasonable but uncertain ethical concerns arise when offering different levels of incentives. In short, the present variability in IRB practices regarding incentive use means, by [CONTACT_108], that either (a) incentives are being underutilized, 
creating inefficiencies, potentially sacrificing study completion, and thereby [CONTACT_111541]; or (b) incentive s are being over-
utilized, creating threats to autonomous choice or targeting a “research underclass”. The current trial is 
necessary to improve upon this worrisome status quo, and hence has the potential to make the entire 
practice of clinical trials more  ethical.  
 
There is no alternative to address the scientific question in a valid manner but to use 
deception/incomplete disclosure.  
 
 
 
[ADDRESS_124179] (RTOG 1308 , BASC , 
and MOVE IT)  with out the incomplete disclosure related to the random assignment of financial 
incentives. Indeed, any disclosure about the random assignment of incentives would thwart the ability 
to measure either the intended or the potential unintended consequences of research incentives. To 
definitively address the ethics, effectiveness, and cost effectiveness of incentives for research 
participation, high -quality evidence is needed, and to date, studies of incentives to participate in 
hypothetical RCTs of common interventions, as well as small studies in non -generalizable cohorts, do 
not fully answer whether the ethical concerns of financial incentives actually manifest.  
 
Subjects cannot be informed prospectively of the use of deception/incomplete disclosure and consent 
to its use.  
 
Prospectively informing patients in even a general way would sabotage the goals of the research 
because it would create a cognitive state (decision -making context) that is fundamentally different from 
that which future patients encountering future incentives would have at corresponding times. Because 
this trial is fundamentally about choices made by [CONTACT_111542], and how risks and incentives might modify those choices, any extraneous factors that could also modify decisions or 
choices must be avoided. Following the debriefing, all eligible patients will be given the opportunity to 
ask any questions regarding the incentives study. The parent trial nurse/staff will then explain that all participants actually will receive the full $1,200 payment and he or she will detail the plans for 
disbursement.  
9. Study Calendar s 
 
The following calendar reflects the procedures as they are described in Section 8. 
a. RTOG 1308  Study Calendar  
 
Study calendar for RETAIN and Phase III Randomized Trial Comparing Overall Survival After Photon 
Versus Proton Chemoradiotherapy for Inoperable Stage II -IIIB Non -Small Cell Lung Cancer. 
Week  0c 0-1C 7-8C/M 
Screening and Eligibility (RTOG 1308)  X X  
1308 Video  X    
RETAIN Eligibility Prompts  X    
Informed Consent for Research Attitudes 
Study (RETAIN Study Consent)  X    
Demographics  X    
Economic Well -Being  X    
Research Attitudes Questionnaire  X    
Prior  Research Experience  X   
 
 
 
37 
 Informed Consent Administration (RTOG 1308 
Parent Trial)  X    
Compared Riskiness Scale  X    
Therapeutic Misconceptions     
Trial Elements Quiz  X    
Review answers + Patient Q &A  X    
Informed Consent Signing (RTOG 1308 Parent 
Trial)  X    
Perceived Coercion and Prior Persuasion 
Questions  X   
Debriefing   X      
[At simulation or 
next in -person 
appointment]   
Payment   X 
[First Installment 
Disbursed as soon 
as possible after 
debriefing]  X 
[Second Installment 
Disbursed during 
Final Week of 
Treatment]  
 C=clinic visit (in -person session)  
M= no visit or call  
 
b. BASC  Study Calendar  
 
Study  calendar for RETAIN and Behavioral Activation and Varenicline for Smoking Cessation in 
Depressed Smokers .  
Week  0P 0c 0p 1c 27P 
Screening and Eligibility  (BASC ) X X    
RETAIN Eligibility Prompts       
Demographics  X  
   
Economic Well -Being  X  
   
Research Attitudes 
Questionnaire  X  
   
Prior Research Experience  X  
   
Compared Riskiness Scale  X     
Informed Consent 
Administration ( BASC  Trial)   X     
Compared Riskiness Scale   X     
Therapeutic Misconceptions   X    
Trial Elements Quiz   X     
Review answers + Patient Q &A   X     
Informed Consent Signing ( BASC  
Trial consent)   X     
Perceived Coercion and Prior 
Persuasion Question   X    
Debriefing    X        
Payment     X X 
 
 
 
38 
 [First 
Installment of 
150 disbursed as 
soon as possible 
after debriefing]  [Second 
Installment of 
150 
disbursed 
during final 
week of 
treatment]  
 P= phone  
C=clinic visit (in -person session)  
 
c. MOVE IT Study Calendar  
 
Study calendar for RETAIN and Mobility, Outcomes, and Validated Experience s Incentive Trial (MOVE 
IT).  
Week  0c 1c 13M 
Screening and Eligibility  X   
Demographics  X   
Economic Well -Being  X   
Research Attitudes 
Questionnaire  X   
Previous Research Experience  X   
Informed Consent 
Administration (MOVE IT Trial)  X    
Compared Riskiness Scale  X    
Therapeutic Misconceptions  X   
Trial Elements Quiz  X    
Review answers + Patient Q 
&A X    
Informed Consent Signing 
(MOVE IT Trial consent)  X    
Perceived Coercion and Prior 
Persuasion Question  X   
Debriefing  X        
Payment   X 
[First Installment of 
150 disbursed as soon 
as possible after 
debriefing]  X 
[Second Installment of 150  
disbursed during final 
week of intervention]  
 
 
 
39 
  P= phone  
C=clinic visit (in -person session)  
M=Mail – no visit or call  
 
10.  Data Management  
a. Data Collection and Data Confidentiality  
 
Prudent steps will be taken to ensure that all information will be kept confidential and secure, including 
medical and survey data as well as social security numbers. Unique patient identifiers will be assigned 
to each subject locally.  
i. RTOG 1308  
 
Survey data will be collected on- site by [CONTACT_111543] (Research 
Electronic Data Capture), hosted at the University of Pennsylvania, for the RTOG [ADDRESS_124180] 
Manager will maintain the database with oversight from the key study personnel.  
 
The parent trial recruitment teams at each site will maintain their own patient screening databases to 
track information such as when eligible patients will be in clinic; date of biopsy;  when they completed 
study measures; when they might be returning to clinic, dates of consent; as well as when payments are 
disbursed. Data from the screening process specifically for patients who become RETAIN subjects will be 
entered into REDCap to enable its inclusion in data extracts. All other information about the combined 
screening process will be provided to the RETAIN project manager as aggregate numbers only.  
 
All datasets and computer files and study ID numbers will be further secured as follows. We will 
implement multiple, redundant protective measu res to guarantee the security of participant data. All 
data for this project will be stored on the secure and firewalled servers of the Center for Clinical 
Epi[INVESTIGATOR_69637] (CCEB). These data servers are maintained in a guarded facility behin d 
several locked doors, with very limited physical access rights. Electronic access rights are carefully controlled by [CONTACT_111544]. We will use highly secure methods of data encryption for all transactions involving participants’ financial informa tion, such as W -9 forms, using a level of security 
comparable to what is used in commercial financial transactions.  This multi -layer system of data 
security, identical to the system protecting the University of Pennsylvania Health System’s medical records,  greatly minimizes privacy risks.  
 Only authorized personnel will have access to the data. All of these personnel will have completed research and confidentiality training (specifically, CITI training). Through REDCap, each study subject will 
 
 
 
40 
 be given a u nique study identification number (ID). By [CONTACT_15094], all direct identifiers will be omitted from 
data extracts, and the study ID will be used exclusively in all analytical files.  
 
Records containing subjects' social security numbers will be maintained, used , and destroyed according 
to Penn's social security number policy. Any paper records collected for regulatory purposes or as 
backup for direct electronic data entry will be kept in locked filing cabinets at the site where they were 
collected. All data will be destroyed after 7 years.  
ii. BASC   
 
Survey data will be collected via phone and in -person using a Case Report Form format for the RETAIN -
BASC  partnership. The BASC  Penn database manager will oversee the database management system 
(DMS ) for this trial.  The DMS is an MS Access  database that permits real -time data entry, storage, and 
QA by [CONTACT_111545], which increase standardization across 
personnel.  
 
The DMS generates database tables in a NIH -compli ant format, constructs semantic constraints on 
fields, and is used for data entry, storage, retrieval, and security. The DMS uses session dates to describe procedures and measures to be ascertained.  The DMS mimics the appearance of CRFs 
completed at sessio ns. Daily backups occur to protect against accidental corruption or deletion.  The 
Penn BASC  research staff will compare 100% of hard copy to computer data. Protection of participant 
privacy is accomplished by [CONTACT_111546] , use of ID numbers rather than 
participant names, keepi[INVESTIGATOR_111471], and strictly limiting access to the dataset that links 
participant names with ID numbers.  
 
Every touchpoint with participants is “milestoned” (e.g., attended, missed, scheduled)  in the trial 
database to ensure subject tracking through the trial. The RETAIN team will work with the BASC  study 
team to ensure all RETAIN -relevant screening outcomes are adequately milestoned within the DMS.  
 
For measures of time spent reading the BASC  parent trial consent form, BASC  research staff will use 
REDCap at the eligibility intake session. The same pr ocedures described in Section [ADDRESS_124181] to Health platform for the MOVE IT partnership. 
Penn Medicine Academic Computing Services (PMACS) supports  the computing infrastructure that will 
be used for  the MOVE IT study , including the Way to Health web portal. PMACS is a joint effort of the 
University of Pennsylvania's Abramson Cancer Center, the Cardiovascular Institute, the Department of 
Pathology, and the Leonard Davis Institute. PMACS provid es a secure computing environment for a 
 
 
 
[ADDRESS_124182] (HIPAA) training and covers secure data transfer, passwords , computer security 
habits and knowledge of what constitutes misuse or inappropriate use of the server. All investigators 
and research staff with direct access to the identifiable data will be required to undergo annual 
responsible conduct of research, cyb ersecurity, and HIPAA certification in accordance with University of 
Pennsylvania regulations.  
 
All data will be stored and analyzed on institutionally managed and secured servers with access 
privileges limited to those with a need to know via the use of single -user access passwords and 
usernames . All study personnel that will use this data are listed on the IRB application and have 
completed training in HIPAA standards and human subjects research. Whenever possible, direct 
identifiers will be removed from  analysis files.  
 
Screening data, as well as the RETAIN  randomization  step , scripts, and data collection for  time spent 
reading the MOVE IT parent trial consent form, will be integrated into a REDCap  database . The same 
procedures described in Section 10.a.[ADDRESS_124183] confidentiality. An investigator or statistician who logs in will be able to 
download only de - identified data. Parent trial research staff at the different sites will not b e able to 
access information from other sites; we will put in place data user groups in the REDCap system. Only 
parent trial research staff responsible for contact[CONTACT_111547] -up meetings or responding 
to questions about the study will be ab le to view participant names and contact [CONTACT_3031]. This 
personal information will be used to contact [CONTACT_111548], 
payments, or they contact [CONTACT_111549] a problem. We will implement multiple, redundant protective 
meas ures to guarantee the privacy and security of the participant data. All study data will be stored on 
the secure/firewalled servers at the University of Pennsylvania. These data servers are maintained in a guarded facility behind several locked doors, with very limited physical access rights. They are also 
cyber -protected by [CONTACT_111550]. Electronic 
access rights are carefully controlled by [CONTACT_111551]. We believe this multi- layer system of 
data security, identical to the system protecting the University of Pennsylvania Health Systems medical 
records, greatly minimizes the risk of loss of privacy.  
 
 
 
[ADDRESS_124184] subjects' names, addresses, phone numbers, and data required for the completion of W -
[ADDRESS_124185], we will develop and implement 
methods of verifying entered data and of quality control among parent trial research staff who will be 
directly entering data into the REDCap system. Second , the PI [INVESTIGATOR_111472], protocol deviations/violations and unanticipated events to the 
IRBs and funding agency promptly, as appropriate. The PI [INVESTIGATOR_111473], acc rual 
rates, retention rates, and all other logistical issues to the DSMB at least biannually (if there are serious adverse events  occur at any time that the investigators feel ought to be brought to the attention of the 
DSMB sooner, the DSMB can also meet on an ad hoc basis ). Third, there will be a DSMB responsible for 
monitoring the trial, convening for the first time in December [ADDRESS_124186] includes the following members:  
Jennifer S. Blumenthal -Barby, PhD  (Chair) : expertise in ethical contexts of human judgment and decision -
making in human research.    
Salma Jabbour, MD : expertise in  radiation oncology with a subspecialty in lung cancer.  
Brenda F. Kurland, PhD : expertise in  biostatistics with research emphasis on longitudinal and other 
correlated data.  
Jeffrey M. Peppercorn, MD, MPH : expertise in medical oncology with research emphasis on bioethics 
and health policy, as well as cancer survi vorship.  
Kim Vernick : member of th e University of Pennsylvania’s Proton Patient Alumni Program , Patient and 
 
 
 
43 
 Family Advisory Council, and a cancer survivor .  
The PI  (Scott Halpern) , assisted by [CONTACT_74143] , will be responsible for maintaining 
communication between the DSMB and the individual project staff.  The DSMB will be responsible for 
monitoring the trial and making decisions about the termination of individual study arms or the study 
itself. The DSMB will review and approve the research protocol. They will also assess the progress of the 
trial, including the assessment of data quality, participant recruitment, accrual and retention, participant 
risk versus benefit, and study outcomes.  Corresponding re commendations will be issued at all 
subsequent meetings. These recommendations will be based on the results and discussion of interim 
analyses, conducted at one -half, and three- fourths of the target same size. DSMB recommendations may 
be guided by [CONTACT_111552]. The DSMB may recommend permanent suspension of 
enrollment, or temporary suspension pending protocol modification. Following each meeting, and the provision of recommendations and the response from the research team, the Principal Investigator [INVESTIGATOR_111474]. Prior to submission to these IRBs, 
the progress reports will be approved by [CONTACT_2020].  
c. Stoppi[INVESTIGATOR_111475], in consultation with Co -Investigator and Faculty Statistician [CONTACT_111601] -Shields, has 
identified TWO trial stoppi[INVESTIGATOR_004].  The DSMB approved these stoppi[INVESTIGATOR_111476]: 
1. Early evidence of undue inducement that distorts voluntary informed consent. To detect whether 
incentives represent undue inducement, the research team will test the statistical interaction between 
incentive size and risk perception on the outcome of enrol lment in the parent RCT s. A statistically 
significant interaction, in the direction that risk perception is less strongly associated with enrollment in higher -payment arms, would be grounds for terminating the trial or suspending a trial arm.  
 
2. Early eviden ce of unjust inducement by [CONTACT_111553] (a) lower income, or (b) reduced financial well -being . Two interaction  term s will be 
evaluated in separate model s to avoid collinearity . Unjust inducement will be defined as a statistically 
significant interaction between (a) incentive size and annual household income, or (b) between 
incentive size and economic well -being , each on the outcome of trial enrollment . One or both of these 
interactions, if statistic ally significant in the direction that lower -income persons or persons with 
reduced economic well -being are more strongly motivated to participate by [CONTACT_111554], will be considered grounds for terminating the trial or suspending a trial arm.  
 
Analyses of these interaction terms will be structured as tests o f non-inferiority, enabling the research 
team to exclude the presence of undue or unjust inducements if the interactions do not manifest. 
Specifically, the research team will use one -sided alpha levels of 0.05 to exclude, with 95% confidence, the 
possibility that any of these interaction odds ratios are >2.0. The interim tests will use [ADDRESS_124187] inducement. Interim 
analyses will be conducted at  one-half, and three -fourths of the target sam ple size.  
The DSMB may also wish to consider i ncrease d rates of therapeutic misconception  as grounds for early 
termination of the trial. The research team will compare responses to the trial’s measure of the construct 
of therapeutic misconception across the three trial arms . While no pre -specified statistical monitoring 
guidelines are proposed for this measure, DSMB members may consult with [CONTACT_111610], with whom the 
therapeutic misconception tool for the trial has been developed, for guidance on interpreta tion of the data 
provided in the open statistical report. [CONTACT_32246] is Senior Investigator in the Department of Bioethics at the 
NIH, and a member of the trial’s External Advisory Board. He is an expert in the use of these measures and 
can provide independent guidance on their interpretation.  
d. Adverse Events  
 
As this is a minimal risk study, we do not anticipate adverse events; however, we will report all adverse events to the Data and Safety Monitoring Board.  
e. Clinicaltrials.gov  
 
The RETAIN  trial has been  registered on clinicaltrials.gov  ([STUDY_ID_REMOVED]) . The study profile will be regularly 
updated on the website and summary results uploaded to make information about the study publicly 
available and promote transparency.   
12.  Human Subjects Protection   
a. Potential  Study Risks  
 
A primary risk to this study is that financial incentives either unfairly induce  participants to participate in a 
trial that they would not otherwise participate in. This is a primary question of this trial. We will convene 
a data and safety monitoring board (DSMB) in conjunction with NIH to monitor any indication that this is 
occurring. Our hypothesis is that no population will be unfairly manipulated into participating in a trial that 
they would not otherwise, and that financial incentives c ould lead to participants examining the potential 
risks of a study more closely than they would have otherwise.  
Supporting Research  
A study led by [CONTACT_976] [INVESTIGATOR_111477] -I Karlawish assessed 126 hypertensive patients’ willingness to 
participate in RCTs of expe rimental antihypertensive drugs.7  We used a 3 x 3 within -subjects factorial 
design in which hypertensive patients were administered, in random sequence, 9 hypothetical RCTs which differed in their risk level (10%, 20%, or 30% chance of drug -related adverse events) and payment 
($100, $1,0 00, or $2,000 for a 10 -week trial). We found that increasing payments motivated greater RCT 
 
 
 
45 
 participation, and that increasing risk levels reduced participation levels (p < 0.001 for each). 
Importantly, patients’ participation rates declined equivalently w ith increasing risk levels across all 
payment levels studied, and the statistical interaction between risk and payment was not statistically 
significant (p=0.30).   This shows that patients were equally sensitive to risk despi[INVESTIGATOR_111478], suggesting that research incentives are not undue inducements.   
Furthermore, this study of payments for RCT enrollment,[ADDRESS_124188] participation study,7 there was an indication that larger 
payments may preferentially motivate wealthier people to participate (payment -by-income interaction 
p=0.09). The validity of these results is enhanced by [CONTACT_111555] -by-payment interactions if they existed.  
Co-I Volpp and colleagues asked participants to rate the riskiness of a new technolog y (transcranial 
magnetic stimulation) being tested in RCTs after being told they would receive $25 or $1,000 for trial participation.
8 Participants assigned to review the trials offering $1,000 spent more time reading about 
study risks a nd other research aspects (mean = 3.7 minutes) than did patients assigned to trials offering 
$25 (mean = 1.0 minutes) (p < 0.01). Larger incentives also decreased the odds that participants would 
skip the page of the informed consent form that described st udy contraindications (p < 0.05). These 
findings suggest that payments alert people to the possibility of risk, and encourage them to learn more about the study.
[ADDRESS_124189] of human subjects research more generally. The 
participants will be debriefed about the purpose of this study and the knowledge to be gained from it.  
 
 
 
46 
 c. Risk/Benefit Ana lysis  
 
In light of the tremendous benefits to public health and individuals developi[INVESTIGATOR_111479], 
as well as our efforts, outlined above, to mitigate all risks associated with this study, we believe that this 
study presents a highly favorable  risk-benefit ratio for participation.  
d. Protective Measures  
 
The first safeguard for protection of human subjects includes an experienced and well -trained study 
team. [CONTACT_111611] (PI) is Associate Professor of Medicine, Epi[INVESTIGATOR_623], and Medical Ethic s & 
Health Policy at Penn, Director of the Palliative and Advanced Illness Research (PAIR Center, and Deputy 
Director of the Center for Health Incentives and Behavioral Economics (CHIBE) at the Leonard Davis 
Institute of Health Economics. He has considerab le expertise in the design, ethics, and recruitment 
barriers of clinical trials, in leading RCTs of financial incentives to modify health behaviors, and in the 
ethics of using behavioral economic approaches, including incentives, to modify health -related 
decisions.  
i. RTOG [ADDRESS_124190]. Liao also serves as the overall Chair of this trial. These 
Co-I’s are among the nation ’s leading clinical researchers in radiation oncology, and have considerable 
influence on related policy. The RETAIN  trial will also harness the support from  key research staff from 
the Department of Radiation Oncology at the University of Pennsylvania’s P erelman Center for 
Advanced Medicine (PCAM).  
In conjunction with the planning and implementation support provided by [CONTACT_111556]’s 
Radiation Oncology Group, [CONTACT_32649] and the University of Pennsylvania research team will also work 
closely with leadership at NRG Oncology, the NCI cooperative group with oversight of the parent trial 
RTOG 1308. NRG Oncology will provide ongoing guidance to ensure that the goals of the  RETAIN study 
align with the goals of the parent trial protocol with respect for hu man research protection.  
RTOG 1308 study supports research nurses/staff at the four  sites participating in the incentives trial. In 
advance of the January 2016 launch of the incentives trial, key study personnel from the University of 
Pennsylvania will eng age with the parent trial nurses/staff, who have been pre -selected by [CONTACT_111557] 
[ADDRESS_124191]. Hitsman’s current collaborations with Penn inclu de 
the Abramson Cancer Center - sponsored Extended Duration Varenicline for Smoking Among Cancer 
Patients ([STUDY_ID_REMOVED]) and the NCI -sponsored project described in this report, Behavioral Activation 
and Varenicline for Smoking Cessation in Depressed Smokers ([STUDY_ID_REMOVED]) – both of which involve 
Penn colleague [CONTACT_111606], who has also successfully collaborated with the RETAIN PI [INVESTIGATOR_111480].  Both 
Drs. Hitsman and Schnoll have experience layering social behavioral manipulations onto existing 
smoking cessation studies to address recruitment challenges, a s well as research focuses that are 
geared toward the recruitment of vulnerable patients.  
iii. MOVE IT  
 
Ryan Greysen, MD, MHS, MA, Section Chief of Hospi[INVESTIGATOR_45047], will co -lead the implementation of the 
MOVE IT study at Penn, in collaboration with Drs. Patel (Co-I) and Halpern. [CONTACT_111608]’s expertise in 
patient -oriented research targeting vulnerable older adults with multiple comordities -- with particular 
focus on improving both hospi[INVESTIGATOR_111481] --will be leveraged to integrate RETAIN procedures 
in a way that is at once sensitive to the inpatient care environment and scientifically sound. [CONTACT_111608] 
will lead the MOVE IT study protocol with Site PI [INVESTIGATOR_111482], MD, MBA, MS. An expert in digital health 
initiatives to improve health outcomes and change health behaviors, [CONTACT_33749] is well- equipped to 
operationalize the integration of the RETAIN trial into the mobility study at the Hospi[INVESTIGATOR_71972], having significant content expertise in the use of incentives within a hospi[INVESTIGATOR_111483].   
e. Additional Protective Measures  
 
To guide the ethical and scientific conduct of this study, and to help posit ion the results so that they 
may have maximal impact on future research efficiency and regulation, we have assembled an External 
Advisory Board (EAB) and an Internal Advisory Board (IAB). The External Advisory Board includes: 
Christine Grady, MSN, PhD, Chief of the NIH Clinical Center’s Department of Bioethics and Head of the 
Section on Human Subjects; Scott Kim, MD, PhD, Senior Investigator in the NIH Department of 
Bioethics; Leslie Wolf, JD, MPH, Professor at the Georgia State School of Law’s Center for L aw Health 
and Society; Timothy Coetzee, PhD, Chief Advocacy and Research Officer for the National MS 
Foundation; and Barbara Langloss, Patient Advocate and an alumna of Penn’s Proton Therapy Program. 
Our Internal Advisory Board includes: Steven Joffe, MD, MPH, pediatric oncologist and Vice Chair of the 
Department of Medical Ethics and Health Policy at Penn; Ezekiel Emanuel, MD, PhD, Chair of the 
Department of Medical Ethics and Health Policy at Penn; and David Festinger, PhD, Adjunct Assistant 
Professor of Psychiatry at Penn and Direct of the Treatment Research Institute’s Section on Law and 
Ethics Research.  
 
 
 
[ADDRESS_124192] protection and will ensure that pati ents (1) understand the recruitment for the parent 
trial included a study on the effects of incentives on study enrollment; (2) understand they were 
randomized to receive one of three study incentives (3) understand they were not informed about the RETAIN  study to avoid biasing the study results; and (4) understand no further data are to be collected 
as part of the RETAIN  study and the study will complete as soon as the incentives are disbursed.  
Additional layers of protection for human subjects include the robust informed consent process (Section s 8.d.-8.e.), excep tional data security ( Section 10 ), and the empowered Data Safety and 
Monitoring Board ( Sections 11.a  and 11.b ), all described in detail in this protocol.  
 
13.  References  
 
1. Halpern SD. Financial Incentives for Research Participation: Empi[INVESTIGATOR_111484], Available Answers 
and the Burden of Further Proof. American Journal of the Medical Sciences. Oct 2011;342(4):290 -
293.  
2. National Institutes of Health Office of Human Subjects Research. Guidelines for remuneration of research subjects in the intramural research program and registration in the clinical research volunteer program database.  Accessed December 3, 2011 at http://ohsr.od.nih.gov/info/pdf/InfoSheet20.pdf
. 
3. Macklin R. 'Due' and 'undue' inducements: On paying money to research subjects. IRB: a review of human subjects research. 1981;3(5):[ADDRESS_124193] to payment? JAMA. 1997;278:199 -200.  
5. McNeil P. Paying people to participate in research: why not? Bioethics. 1997;11:390 -396.  
6. Bentley JP, Thacker PG. The influence of risk and monetary payment on the research particip ation 
decision making process. J Med Ethics. June 1, 2004 2004;30(3):293- 298.  
7. Halpern SD, Karlawish JHT, Casarett D, Berlin JA, Asch DA. Empi[INVESTIGATOR_111485]. Archives of 
Internal Medicine. 2004;164:801 -803.  
8. Cryder C, London AJ, Volpp KG, Loewenstein G. Informative Inducement:  Study Payment as a Signal 
of Risk. Social Science & Medicine. 2010;70(3):455- 464.  
9. Altman DG. Statistics and ethics in medical research III: How large a sample? Br Med J. 
1980;281:[ADDRESS_124194] those who serve. New England Journal of Medicine. 2000;343:1643 -
1645.  
11. Ellenberg SS. Randomization designs in comparative clinical trials. N Engl J Med. 1984;310(21):1404 -
1408.  
12. Freiman JA, Chalmers TC, Smith H, Jr, Kuebler RR. The importance of beta, the type II error and sample size in the design and interpretation of the randomized controlled trial: survey of 71 
"negative" trials. N Engl J Med. 1978;299:690 -694.  
13. Meinert CL. Clinical trials: Design, conduct, and analysis.  [LOCATION_001]: Oxford University Press; 1986.  
14. Nass SJ, Moses HL, Mendelsohn J. A national cancer clinical trials system for the 21st century: 
Reinvigorating the NCI Cooperative Group Program.  Washington, D.C.: The National Academies 
Press; 2010.  
 
 
 
49 
 15. Freedman B. Scientific value and validity as ethical requirements for research: A proposed 
explication. IRB: Rev Hum Subjects Res. 1987;9(6)):[ADDRESS_124195] of underpowered clinical 
trials. JAMA. 2002;288:358 -362.  
17. Kramer MS, Shapi[INVESTIGATOR_111486]. Scientific challenges in the application of randomized trials. JAMA. 1984;252(19):2739- 2745.  
18. Nathan RA. How important is patient re cruitment in performing clinical trials? Journal of Asthma. 
1999;36(3):213 -216.  
19. Hunningshake DB, Darby [CONTACT_28474], Probstfield JL. Recruitment experience in clinical trials: Literature summary and annotated bibliography. Controlled Clinical Trials. 1987;8:6S -30S. 
20. Probstfield JL, Wittes JT, Hunningshake DB. Recruitment in the NHLBI population -based studies and 
randomized clinical trials: data analysis and survey results. Controlled Clinical Trials. 1987;8:141S -
149S.  
21. Vollmer VM, Osborn ML, Hertert S, et al. Recruiting hard -to-reach subjects: Is it worth the effort? 
Controlled Clinical Trials. 1994;15:154 -159.  
22. Emanuel EJ, Schnipper LE, Kamin DY, Levinson J, Lichter AS. The costs of conducting clinical research. J Clin Oncol. Nov 15 2003;21(22):4145- 4150.  
23. Caldwell PH, Hamilton S, Tan A, Craig JC. Strategies for increasing recruitment to randomised 
controlled trials: systematic review. PLoS Med. 2010;7(11):e1000368.  
24. Donovan J, Mills N, Smith M, et al. Quality i mprovement report: Improving design and conduct of 
randomised trials by [CONTACT_111558]: ProtecT (prostate testing for cancer 
and treatment) study. BMJ. October 5, 2002 2002;325(7367):766- 770.  
25. Sugarman J, Kass NE, Goodman SN, Perentesis P, Fernandes P, Faden RR. What patients say about 
medical research. IRB: A review of human subjects research. 1998;20(4):1- 7. 
26. Wendler D, Krohmal B, Emanuel EJ, Grady C, Grp E. Why patients continue to participate in clinical 
research. Archives of Internal Medicine. Jun 23 2008;168(12):1294 -1299.  
27. Halpern SD. Prospective preference assessment: A method to enhance the ethics and efficiency of randomized controlled trials. Controlled Clinical Trials. 2002;23:2 74-288.  
28. Shah A, Efstathiou JA, Paly JJ, et al. Prospective preference assessment of patients’ willingness to participate in a randomized controlled trial of intensity -modulated radiotherapy versus proton 
therapy for localized prostate cancer. Internati onal Journal of Radiation Oncology*Biology*Physics. 
2012;83:E13- E19.  
29. Carroll R, Antigua J, Taichman DB, et al. Pulmonary arterial hypertension patients' willingness to 
participate in randomized clinical trials of novel therapi[INVESTIGATOR_014]. Clinical Trials. 2010;9:348 -357.  
30. Halpern SD, Karlawish JHT, Casarett D, Berlin JA, Townsend RR, Asch DA. Hypertensive patients' 
willingness to participate in placebo -controlled trials: Implications for recruitment efficiency. 
American Heart Journal. 2003;146:985- 992.  
31. Slomka J, McCurdy S, Ratliff EA, Timpson S, Williams ML. Perceptions of financial payment for 
research participation among african -american drug users in HIV studies. Journal of General Internal 
Medicine. Oct 2007;22(10):1403 -1409.  
32. Stunkel L, Grady C. Mo re than the money: A review of the literature examining healthy volunteer 
motivations. Contemporary Clinical Trials. May 2011;32(3):342 -352.  
33. Dunn LB, Kim DS, Fellows IE, Palmer BW. Worth the risk? Relationship of incentives to risk and 
benefit percepti ons and willingness to participate in schizophrenia research. Schizophr Bull. Jul 
2009;35(4):730 -737.  
34. Dickert N, Emmanuel E, Grady C. Paying research subjects: An analysis of current policies. Annals of 
Internal Medicine. 2002;136:368 -373.  
 
 
 
50 
 35. Grady C,  Dickert N, Jawetz T, Gensler G, Emanuel E. An analysis of U.S. practices of paying research 
participants. Contemp Clin Trials. 2005;26:365 -375.  
36. Emanuel EJ. Ending concerns about undue inducement. Journal of Law Medicine & Ethics. Spr 
2004;32(1):100 -105. 
37. Emanuel EJ. Undue inducement: Nonsense on stilts? American Journal of Bioethics. Sep- Oct 
2005;5(5):9- 13. 
38. Emanuel EJ, Currie XE, Herman A. Undue inducement in clinical research in developi[INVESTIGATOR_14696]: is it a worry? The Lancet. 2005;366(9482):336- 340.  
39. Hyun I. Fair payment or undue inducement? Nature. 2006;442(7103):629- 630.  
40. Martin R. Undue inducement in clinical research. Lancet. 2005;366(9482):275- 276.  
41. Casarett D, Karlawish JHT, Asch DA. Paying hypertension research subjects. Journal of General 
Internal Medicine. 2002;17:650 -652.  
42. Wilkinson M, Moore A. Inducement in research. Bioethics. 1999;11:373 -389.  
43. Elliott C, Abadie R. Exploiting a research underclass in phase 1 clinical trials. New England Journal of Medi cine 2008;358:2316 -2317.  
44. Denny CC, Grady C. Clinical research with economically disadvantaged populations. Journal of Medical Ethics. July 1, 2007 2007;33(7):382 -385.  
45. Viens AM. Socio -economic status and inducement to participate. American Journal o f Bioethics. 
2001;1(2).  
46. Wertheimer A. Should we worry about money? Rethinking the ethics of clinical research. [LOCATION_001]: 
Oxford University Press; 2011:117 -190.  
47. Bernstein M. Payment of research subjects involved in clinical trials is unethical. Journal of Neuro -
Oncology. Jul 2003;63(3):223- 224.  
48. Burt RA. On gnats, camels, and payment to research subjects: A comment. Journal of Medicine and Law. 2005;9:25 -30. 
49. Grant RW, Sugarman J. Ethics in human subjects research: Do incentives matter? Journal of 
Medicine and Philosophy. Dec 2004;29(6):717- 738.  
50. Dickert N, Grady C. What's the price of a research subject? Approaches to payment for research participation. N Engl J Med. 1999;341:198 -203.  
51. Halpern SD, Raz A, Kohn R, Rey M, Asch DA, Ree se P. Regulated payments for living kidney 
donation: an empi[INVESTIGATOR_111487]. Ann Intern Med. Mar 16 2010;152(6):358- 365.  
52. Kim S, Kim H, McCallum C, Tariot P. What do people at risk for Alzheimer disease think about 
surrogate consent for research? Neurology. 2005;65:1395 –1401.  
53. Karlawish J, Rubright J, Casarett D, Cary M, TenHave T, P S. Older adults’ attitudes toward non -
competent subjects participating in Alzheimer's research. American Journal of Psychiatry. 
2009;166(2):182- 188.  
54. Muroff J, Hoerauf S, Kim S. Is psychiatric research stigmatized? An experimental survey of the 
public. Schizophrenia Bulletin. 2006;32:129 -136. 
55. Henderson GE. Is Informed Consent Broken? American Journal of the Medical Sciences. Oct 2011;342(4):267- 272.  
56. Bialkova S, van Trijp HCM. An efficient methodology for assessing attention to and effect of 
nutrition information displayed front -of-pack. Food Quality and Preference. 2011;22:592 –601.  
57. Pi[INVESTIGATOR_3689] R, Warlop L. Visual attention during brand choice: The impact of time pressure and task 
motivation. International Journal of Research in Marketing. 1999;16:1 -16. 
 
 
 
51 
 58. Munafò MR, Roberts N, Bauld L , Leonards U. Plain packaging increases visual attention to health 
warnings on cigarette packs in non -smokers and weekly smokers but not daily smokers. Addiction. 
2011;106(8):1505– 1510.  
59. Kim SH WR, De Vries R, Kim H, Holloway R, Kieburtz K. Could the Hi gh Prevalence of Therapeutic 
Misconception Partly Be a Measurement Problem? IRB: Ethics & Human Research 2015;37(4):11.  
60. Kim SH SL, Wilson RM, Frank SA, Holloway RG, Keiburtz K, De Vries RG. An Approach to Evaluating 
the Therapeutic Misconception. IRB: Ethics & Human Research. 2009;31(5):[ADDRESS_124196], et al. Therapeutic misconception, misestimation and optimism in subjects enrolled in phase I trials. Cancer. 2012;18(118):4571 -4578.  
62. Gardner W, Hoge SK, Bennett N, et al. Two s cales for measuring patients’ perceptions for coercion 
during mental hospi[INVESTIGATOR_063]. Behavioral Sciences and the Law 1993;11:307- 321.  
63. Shea JA, Micco E, Dean L, McMurphy S, Schwartz SJ, Armstrong K. Development of a revised health care system distru st scale. Journal of General Internal Medicine. 2008;6(23):727- 732.  
64. Israni AK, Halpern SD, McFadden C, et al. Willingness of dialysis patients to participate in a randomized controlled trial of daily dialysis. Kidney International. Mar 2004;65(3):990- 998. 
65. Shea JA ME, Dean LT, McMurphy S, Schwartz JS, Armstrong K. . Development of a Revised Health Care System Distrust Scale. Journal of General Internal Medicine. 2008;26(6):[ADDRESS_124197] 21, 2017  
 
a. Phase I –  Removal of the University of Pennsylvania as a Recruiting Site  
 
Due to staff turnover, lack of departmental resources , and the slow accrual of RTOG [ADDRESS_124198]. Louis, and MGH, where 
accrual for RTOG 1 308 and personnel resources were better positioned for success.  
b. Phase I I – Modification to BASC recruitment script  
The addition of an eligibility probe  in the recruitment script  to ensure that patients with prior 
knowledge of the maximum incentive of $[ADDRESS_124199] 30, 2017  
 
a. Phase I –  Removal of the Healthcare System Distrust Scale  
 
We removed the Healthcare System Distrust Scale from Phase I, the partnership with the lung 
cancer study (RTOG 1308), as this tool was never intended to be used in the study (it was not 
proposed in the NCI -funded protocol), but rather was added as a condition of participation 
following review by [CONTACT_111559]’s (ROPC) review of this trial. 
Once Penn was no longer a Phase I site, the study team determined that it would be optimal to 
remove the tool to reduce assessment burden for lung cancer patients who consent to both RETAIN 
and RTOG 1308. Of note, the Healthcare System Distrust Scale was never proposed for use  in 
Phases II  and III of the study.  
 
b. Phase II –  Modification to BASC screening procedures  
 
The Northwestern and Penn teams adjusted the patient flow such that the phone -based eligibility  
assessment for the smoking cessation study ( BASC ) happen ed before BASC  screeners randomize d 
the participants and revealed  the RETAIN -associated financial incentives amount on screening calls . 
This allow ed the study team to avoid biases in RETAIN that would result from post -RETAIN 
randomization losses.  Subsequent to this change, a ll BASC-eligible participants were assessed for 
RETAIN eligibility via the standard eligibility probe assessing for prior knowledge of RETAIN 
procedures.  
 
 
 
 
53 
 We also removed  the RETAIN verbal consent question about “research attitudes questions” and  
eliminated the practice of placing patients on the RETAIN or non -RETAIN pathway depending on 
their response to the eligibility probe. This approach is consistent to the Phase III MOVE -IT study 
protocol and ensure d uniform approaches across the two minimal risk studies, while also 
optimizing practicability of the research for the BASC  team.  
 
c. Phases II and III -  Modification to the BASC and MOVE -IT debriefing scripts  
 
We removed  the question, “When you agreed to participate in the [MOVE IT or smoking cessation 
study], did you know that all participants would receive up to [maximum RETAIN incentive amount] 
in the end?” from Phase II ( BASC ) and Phase III (MOVE IT) debriefing script s. After speaking with the 
RETAIN study’s biostatistician, we determined that these data would not be useful for analyses, nor 
effective at ascertaining post -hoc contamination in these companion studies.  
3. Approved September  26, 2017  
 
a. Phases II and III - Mod ifications to the Compared Riskiness Scale  
 
It was determined by [CONTACT_20767]’s faculty statistician and data manager that the items in  the 9 -item 
Compared Riskiness Scale  should contain activities that are more aligned in risk -level and the 
probability, as w ell as nature, of consequences of participation in trials like the BASC  and MOVE IT, 
as opposed to the lung cancer trial RTOG 1308. Several items were replaced to better align these 
risky activities and enable a range of responses from participants, includ ing “taking 3 times the 
recommended dose of pain killers;” “receiving stitches;” “riding a motorcycle with no helmet;” 
“getting a body pi[INVESTIGATOR_77219];” and “bungee jumpi[INVESTIGATOR_007].”  
 
4. Approved October  25, 2017  
 
a. Phases II and III –  Clarification of Payment Procedures  
 
Debriefing scripts, recruitment procedures, and FAQs for both BASC and MOVE -IT trials were 
modified to clarify the procedures and timing for subject compensation.  
 
Compensation information available to BASC subjects (if requested) during recruitment:  
  “Wh en do I get compensated (if randomized to the $200/$500)?”  
o For $500 subjects: You will receive up to $500 for completing this study. This includes $150 at the 
beginning of the study, $150 at the end of the study, and the remaining $200 will be disbursed fo r 
attending scheduled visits and completing tasks.  
 
 
 
54 
 o For $200 subjects: You will receive session completion payments up to $200. These are disbursed 
based on your attendance at specific visits.”  
 
Compensation information provided to BASC subjects during debriefing:  
You will be paid a total of $300 in two installments of $150: You will receive the first installment of 
$150 now, and the second installment of $[ADDRESS_124200] that can be used like cash. If you withdraw from the study, you will 
not receive the second payment.  
 
 Compensation information provided to MOVE -IT subjects during enrollment:  
If you withdraw from the study at any point prior to enrollment and completion of today’s questionnaires, 
you will not receive the first payment. If you withdraw for personal reasons or discontinue the use of the 
study’s wearable before the completion of study -related tasks at [ADDRESS_124201] -discharge, you will not 
receive the second payment. I’ll ask that you fill out an electronic W9 form so that we can ensure the 
payment is properly processed.”  
5. Approved November 20, 2017  
 
a. Phase II –  Revision of BASC Debriefing Script  
 
At the requ est of the BASC study team, we abbreviate d the RETAIN debriefing script during the Reminder 
Call (between “intake” and “Pre -Quit 1”) during which participants are informed of the payment scheme 
and goals of the RETAIN study. All participants who sign conse nt at intake and are confirmed eligible by [CONTACT_111560]. The BASC  study team expressed that the information being 
conveyed on the call is dense; participants may not fully appreciate the nuances in payment structure 
between RETAIN and BASC , as well as key eleme nts of the study’s purpose. Subjects will hear the 
abbreviated script on the Reminder Call and then the full, IRB- approved script at their Pre -Quit [ADDRESS_124202] for the purpose.  
c. Phase II –  Revision to Compared Riskiness Scale for BASC study  
 
The team made a minor modification to the introduction of items on the Compared Riskiness Scale for the 
BASC study. Instead of r esearch coordinators  introducing the scale by [CONTACT_3041], “Does participating in this 
 
 
 
55 
 study, versus not  participating, seem…” they will say , “Does participating in this study seem more risky 
than” and go through respective activities, item by [CONTACT_111561] a Yes/No response.  
6. Approved January 3, 2018  
 
a. Phase I –  Termination of RTOG [ADDRESS_124203]. Louis in collaboration 
with a lung cancer parent trial, RTOG 1308, the Phase III Randomized Trial Comparing Overall Survival After 
Photon Versus Proton Chemoradiotherapy for Inoperable Stage II -IIIB NSCLC. This parent trial faced accrual 
challenges from its outset, due largely to insurance denial of proton therapy, which precludes eligibility for 1308. Despi[INVESTIGATOR_111488] 1308 collaborat ion, accrual to 
1308 had  only worsened  through 2018 . A total of 5 patients across all sites had  been enrolled in RETAIN 
through the 1 308 col laboration, and none had been enrolled in the previous  4 months. Indeed, accrual to 
1308 had  been so challenging that the 1308 investigators changed their primary outcome so as to enable a 
reduction in the target sample size for the 1308 trial from 576 to 350. This reduction in the parent trial’s 
target sample size made it impossible for the RETAIN -[ADDRESS_124204] exclusively focused on Phases II and II from the sponsor, the Nation Cancer Institute, on 
November 30, 2017.  
As a result of this change, the team removed  RTOG 1308 -relevant language from the IRB protocol 
and end ed Penn’s oversight of the RETAIN trial at MDACC, a relying institution. The MGH and 
Washington Universit y research teams closed  out the RETAIN study at their respective sites.  
7. Approved January 25, 2018  
 
a. Phase II –  Modification to BASC screening procedures  
 
The study teams for BASC and RETAIN implement ed a  RETAIN -related change to the phone screen script being used 
at Northwestern and Penn. For patients random ized to RETAIN, the team stopped  asking, “Does  this sound like 
something that you are interested in?” before administeri ng the RETAIN surveys.  They simply transition ed from 
introducing the study basics to administering the RETAIN questions by [CONTACT_3041], “Now we ask that you answer a few 
more questions b efore finalizing the details of your intake visit.”  
 
 
 
56 
 The goal of this change was to provide an opportunity to capture RETAIN baseline data that was  not being collected 
systematically due to early withdraws from the phone screen call.  
b. Phases II and III -   Revisions to the Compared Riskiness Scale  
 
The study team examined the phrasing  for the Compared Riskiness scale in an Amazon mechanical Turk study aimed 
at countering floor effects in our measure of risk perception.  As a result of this investigation we made several 
changes to the phrasing of the questions in the scale. We did not add new items to the scale.    
8. Approved February 21, 2018  
 
a. Phase II –  Modification to MOVE IT recruitment procedures  
 
This modification was submitted  in tandem with our colleagues on the Mobility, Outcomes, and Validated 
Experiences Incentive Trial  (MOVE IT) study (IRB # 823491).  With this change  MOVE IT eligibility  was assessed  
earlier in the enrollment process order to randomize and announce the incentives earlier to patients. We also added 
a note to patients randomized to the $100 and $[ADDRESS_124205] installment in a non -check format. 
These  change s were r eflected in the updated debr iefing and consent forms.  
b. Phases II and II I – Modifications to t he Compared Riskiness Scale  
We also updated  the Compared Riskiness scale  once more in an effort  to counter early floor effects.  
9. Approved April 23, 2018 
 
a. Phase III  – Modification to data collection and administration of surveys  
In our modification approved February 21, 2018, we moved the randomization to 1 of 3 incentives to earlier in the 
clinical research coordinators’ recruitment script to optimize the research team’s ability to augment enrollment in 
the MOVE IT study. Patient s who are randomized  in this model  become R ETAIN subjects, and we had a way to  
capture demographic information on RETAIN subjects who decline participation in MOVE IT. However, we did not 
have a means of  capturing risk perception data on patients who decli ned early, before reading the consent form for 
MOVE IT.  To mitigate the issue of data missingness among these patients and to ensure we were able to execu te 
the study successfully, we decided  to include the C ompared Riskiness survey in the  baseline set of  surveys, as well 
as include a minimal description of risks and benefits early in the enrollment script. This modification and change in 
data collection  allow ed us to test the interaction between incentive size and risk perception on the outcome of 
enrollm ent – and detect undue inducement, a key outcome of the study and criterion for the Data Safety and 
Monitoring Board to consider stoppi[INVESTIGATOR_21356].  
 
 
 
 
57 
 10.  Approved January 25, 2019  
 
a. Phase III –  Addition of Qualitative Evaluation of Patient Decision -Making  
We d eveloped a new qualitative study to explore participants’ motivations for enrolling or not enrolling in the 
MOVE IT study. The qualitative study consists of 1) data collection during the enrollment encounter for the 
purposes of conducting a discourse analy sis and 2) semi -structured interviews among participants who decline 
MOVE IT (in -person) and enroll in MOVE IT (2 weeks after discharge from the hospi[INVESTIGATOR_111489]). For the latter, the 
MOVE IT team has added additional questions pertaining to the intervention and patients’ transitions from hospi[INVESTIGATOR_111490]. We engaged Penn’s Mixed Methods Research Lab to support data collection, transcription, coding, and 
analysis; key personnel were added to the IRB application. The MOVE IT research coor dinator also support ed in-
perso n data collection. The addition of this study had no impact on the RETAIN study itself, but the two were linked 
for regulatory/oversight purposes.  
 
   
 
  
  
 
   
 
 
 
 
 
 
 
[ADDRESS_124206] common and conceptually sound1,2 ethical concerns with incentives for research participation 
are that they may (1) represent undue inducements by [CONTACT_111509]’ perceptions of research risks, 
thereby [CONTACT_111510]3-5; or (2) represent unjust inducements by [CONTACT_111511]. Neither of these concerns has been shown to manifest in studies using hypothetical incentives for participating in hypothetical RCTs.
6-[ADDRESS_124207] a randomized trial of 3 real incentives to participate in two parent randomized clinical trials (RCTs).  Following clinicians’ and research staff’s preliminary determination of patients’ eligibility in the parent RCT, we will assess patients’ research attitudes, demographic characteristics, perceived 
research risks, time spen t reviewing informed consent documents, ability to distinguish research from 
individualized patient care, and comprehension of key trial features. These quantitative assessments will 
be supplemented by [CONTACT_31576] -structured interviews for a selected group of par ticipants that more deeply 
explore patients’ motivations for participating in trials, and the relative influence of incentives on those choices.  
After patients make a decision about parent trial enrollment, we will debrief patients consenting to the 
paren t trial about the random assignment of the incentives. The study will have adequate power to rule 
out between incentive size and risk perception (i.e., undue inducement) and between incentive size and 
income or economic well- being (i.e., unjust inducement)  , using formal “non -inferiority” tests, 
interactions. We also will explore potential benefits of incentives, such as the possibilities that incentives 
improve informed consent by [CONTACT_111512], and that they 
expedi te recruitment enough to be cost- saving on balance.  
2. Background and Significance  
 
Recruitment problems often cause randomized clinical trials (RCTs) to fail or accrue excess costs  
 
The concomitant problems of under -enrollment and selective enrollment in randomized clinical trials 
have long plagued efforts to evaluate new and existing medical interventions. 9-13 For example, a recent 
Institute of Medicine report found that 40% of cancer RCTs are never completed and published.14 Under -
enrollment occurs when too few research participants are enrolled to provide adequate statistical power to answer the study’s primary research question. Because under -enrollment yi elds unacceptably high 
probabilities for type II (false negative) errors, these problems reduce the RCT’s ability to answer the 
 
 
 
59 
 research question, thereby [CONTACT_111513]’s scientific value and hence, ethics.15,16    Selective 
enrollment occurs when certain subgroups within the target population enroll in proportions greater or 
less than their representation in that population. By [CONTACT_111514]’s results, this 
problem also curtails scientific value. 17 
These problems typi[INVESTIGATOR_111491], which has 
been called “the most difficult and challenging aspect of clinical trials.18” Even when investigators enroll 
an adequate number of participants, they rarely do so on schedule,13,19,[ADDRESS_124208] costs 
of conducting clinical trials, requiring an average of 13 hours and $[ADDRESS_124209] that financial incentives can increase study enrollment, and that larger incentives are more effective than are smaller ones.
6,7,33  
If financial incentives do indeed increase the enrollment fraction – the number of patients enrolled 
among all patients recruited – they could enhance considerably the scientific value and validity of the 
research by [CONTACT_111515] (i.e., statistical power) of RCTs. Further, because prior studies by [CONTACT_2296]
7,8,[ADDRESS_124210] often -cited concern with paying people to participate in research is that incentives 
represent undue inducements – that is, they might alter peoples’ perceptions of the risks associated with 
research participation, thereby [CONTACT_111562]. 3-5,36 -42 In the face of monetary offers, 
particularly those that are large and immed iate, people may overlook or underestimate a study’s risks, 
and hence consent to participate against their own better judgment. Importantly, an inducement is not undue if it merely encourages people to do things they would not do for free.
36,37,39,[ADDRESS_124211] inducements – that is, 
incentives could encourage enrollment preferentially among less -wealthy persons. Such differences in the 
effects of pa yments may be unjust if they create a system in which the burdens of research participants 
are borne preferentially by [CONTACT_111516], whereas the knowledge gained from the research would benefit all 
 
 
 
60 
 (or worse, benefit the rich preferentially).43-[ADDRESS_124212] despi[INVESTIGATOR_111450] -
advantaged persons commonly incur risks for the be nefit of others (e.g., military service, coal mining), 
1,44,46and that larger payments – rather than none – may be needed to counter concerns regarding 
exploitation.[ADDRESS_124213] changed the 
core question from whether participants should be paid to how much is fair.50 Yet the 2 core concerns 
noted above continue to engender inconsistent policies for regulating incentives by  [CONTACT_111517] (IRBs) and funding agencies.2,[ADDRESS_124214] effectiveness of plausible 
incentive sizes.   
3. Objectives  
a. Aims  
 
Aim I:  The primary aim of the RETAIN trial is to determine if the eth ical concerns with incentives for 
research participation actually manifest.  
By [CONTACT_111563] (see Section 4. Study Organization) to low -, middle -, and high -level incentives for enrolling, and using our established methods for measuring 
the unintended consequences of incentives for participation
1,7,8,51, we will conclusively determine how 
incentives influence perceptions of research risks, and the proportion of economically disadvantaged 
patients who enroll.   
 
Aim II: The secondary aim of the RETAIN trial is to assess the possible scientific and ethical benefits of financial incentives for RCT participation.  
The potential benefits of incentives also are grounded more in theory than in evidence. We will 
empi[INVESTIGATOR_111492] 3 potential benefits, testing whether incentives (1) increase the enrollment rate, 
thereby [CONTACT_111519]’s efficiency; (2) increase participants’ attention to risk information and 
their understanding of the research study, thereby [CONTACT_111520]; and (3) 
reduce the rate of “therapeutic misconceptions,” defined as patients’ failures to appreciate how the goals 
 
 
 
61 
 and processes of research differ from those of clinical care.  
 
Aim III:   The third aim of the RETAIN trial is to evaluate the cost -effectiveness of using financial incentives 
to increase RCT enrollment rates.  
To inform the use or nonuse of incentives requires not only that we understand their scientific and ethical 
pros and cons, but also their economic cost s. To further guide investigators’ and funders’ decisions 
regarding incentive use, we will assess the incremental costs relative to the incremental time saved if an 
otherwise identical RCT was conducted with versus without financial incentives.   
b. Primary Ou tcome Variable  
 
The primary outcome is the proportion of people assigned to each incentive amount that consent to 
participate in two parent RCTs (see Section 4. Study Organization).  
c. Secondary Outcome Variables  
 
1. Attitudes towards research: Attitudes towards research will be measured using the 
Research Attitudes Questionnaire -7 (RAQ- 7).52 The RAQ has high internal consistency and 
factorial validity.53,54 We will me asure the RAQ prior to disclosure of incentives in order to 1) 
assess patients’ broad reasons to participate in research or not without being biased by 
[CONTACT_111521] 2) assess whether the hypothesized relationship between RAQ score and the o dds of enrolling is modified by [CONTACT_111522]. The presence of such effect 
modification would suggest that incentives represent undue inducements.  
2.  Attention to the informed consent document: Attending more carefully to informed 
consent documents may promo te informed choice. 
55 Visual focus has been established as a 
meas ure of attention in several settings, and has been associated with peoples’ 
choices56,57and subsequent recall. 58 We will assess the amount of time patients spend 
reading each part of the parent trial consent form by [CONTACT_111523] a  “survey” 
in REDCap. The data extract will include the time – to the second –  at which the participant 
moved to another section through a timestamp.  The primary measure of this assessment 
will be time spent on the risk section; the secondary measure will be total time spent on the 
consent form.  
3. Perceived r isks of the research: Perceived risks of the research will be measured by a 
modified 9 -item “compared riskiness” scale, which assesses perceptions of research risk.8   
4. Incidence of therapeutic misconceptions: It has been hypothesized that the use of financial 
incentives could reduce therapeutic misconceptions, and thereby [CONTACT_111564] -making. [ADDRESS_124215]. Scott 
Kim. 59-61  
5. Understanding of the trial:  In preliminary work, we have shown that research incentives 
may encourage potential participants to spend more time learning about study 
elements.7,27 To assess whether increased attention translates into improved understanding 
of the trial, we will use a 6 -item Trial Elements Quiz, featuring core elements of the parent 
trial’s consent form.   
6. Perceptions of influence or coercion: To measure general perception of coercion and 
voluntariness of research participation, we will use the five- item Perceived Coercion Scale 
of the MacArthur Admission Experience Survey62. The true/false scale is tailored to measure 
patients’ perceptions of coercion in the inpatient psychiatric treatment admission process; we have edited the wording to make it relevant to participation in the parent trials.  
7.  Retention through the end of treatment sessions: To assess the impact of incentives on retention status in the protocol, we will disburse payment in two installments - one as soon 
as possible after debriefing and one during the patient’s last week of treat ment therapy or 
study intervention. The denominator for analyses of this outcome will be all those who 
received the first payment. We will assess whether patients completed their treatment, and 
if not, reasons for non -completion.  
Please see Section 8.f . Administration of Survey Instruments and for additional information on the Study 
Instruments used to measure outcomes for the RETAIN trial.  
4. Study Organization  
a. RETAIN Infrastructure  
 
The RETAIN study infrastructure is supported by [CONTACT_111565] s among two different patient 
populations:  
4) The Behavioral Activation and Varenicline for Smoking Cessation in Depressed Smokers Study, 
or BASC , which tests two behavioral interventions in combination with Chantix in a population 
of daily smokers with current or lifetime major depressive disorder (BASC). The primary 
outcome of this trial is point -prevalence abstinence post target quit date (NCT 0 2378714).   
 
5) The Mobility, Outcomes, and Validated Experiences Incentive Trial, or MOVE IT , which targets 
adults admitted for inpatient care on medicine or oncology floors on [ADDRESS_124216] of a hospi[INVESTIGATOR_307] -
implemented mobility protocol for general medical and cancer patients using wearable 
technology. The primary outcome is the change in mean daily step count from the baseline 
period (week [ADDRESS_124217] -discharge) to the intervention pe riod (weeks [ADDRESS_124218] -discharge) 
 
 
 
63 
 ([STUDY_ID_REMOVED] ).  
RETAIN procedures have been layered on each study to maximize practicability for parent trial research 
staff and to align with the scientific goals of each parent trial.  Key differences between the RETAIN s tudy 
design in the context of the three parent trials are further described in Section 5. Study Design.   
b. Research Team  
 
The University of Pennsylvania research team includes investigators with expertise in research ethics, 
clinical trials, biostatistics,  health economics, and in the use of financial incentives to motivate a variety of 
health -related behaviors.  
[CONTACT_111611] (PI) is Professor of Medicine, Epi[INVESTIGATOR_623], and Medical Ethics & Health Policy at Penn, 
Director of the Palliative and Advanced Illness Research (PAIR) Center, and a member of the Steering 
Committee for the Center for Health Incentives and Behavioral Economics (CHIBE) at the Leonard Davis Institute of Health Economics. He has considerable expertise in the design, ethics, and recruitment barriers of clinical trials, in leading RCTs of financial incentives to modify health behaviors, and in the ethics of using behavioral economic approaches, including incentives, to modify health -related decisions.  
[CONTACT_111597] (Co -I) is Director of the CHIBE and PENN -CMU Roybal P30 Center on Behavioral Economics 
and Health. He has successfully completed numerous NIH-funded RCTs of financial incentives to modify health -related behaviors.  
[CONTACT_111598]  (Co-I), Professor of Medicine and Medical Ethics & Health Policy, is one of the nation’s 
leading scholars on patient capacity to consent to research and decisions to enroll in trials. He has extensive experience using many of the instruments to be employe d in this study, and is an expert in interpreting the 
data they produce.  
[CONTACT_111599] (Co -I) is Associate Professor of Family Medicine and Co -Director of Penn’s Mixed Methods 
Research Lab. She has great expertise in the use of qualitative methods in m edical research and will work 
closely with [CONTACT_32649] to oversee the conduct of semi- structured interviews, once implemented, to assess 
patients’ motivations for participating in the RCT.  
[CONTACT_111600] (Co -I) is Professor of Medicine and Executive Director of the Leonard Davis Institute of 
Health Economics. He is a leading authority on economic analyses within RCTs, and will guide our analysis of the cost- effectiveness of incentives for RCT enrollment.  
[CONTACT_111601] -Shields (Co -I), Assistant Profe ssor of Biostatistics in Biostatistics and Epi[INVESTIGATOR_111452], will be the principal biostatistician for this RCT. She has significant expertise in clinical trials and longitudinal data analysis.  
Site Principal Investigators  
BASC 
[CONTACT_111612] (Co -I), Associate Professor of Preventive Medicine and Psychiatry and Behavioral Sciences 
at Northwestern University, is the Principal Investigator [INVESTIGATOR_111457] -funded parent study Behavioral 
 
 
 
64 
 Activation and Varenicline for Smoking Cessation in Depressed Smokers Study (BASC). Dr. HItsman will lead 
BASC parent trial research staff at the Northwestern site in RETAIN recruitment efforts.   
[CONTACT_111605] (Co -I), Associate Professor of Psychology in Psychiatry at the University of Pennsylv ania is 
Site Principal Investigator [INVESTIGATOR_111458] -funded parent study Behavioral Activation and Varenicline for 
Smoking Cessation in Depressed Smokers Study (BASC). [CONTACT_111606] will lead BASC parent trial research staff 
at the Penn site in RETAIN recruitment efforts. Together with Co -I Hitsman, [CONTACT_111606] will work with [CONTACT_32650] to address any issues that arise with recruitment, study execution, or data monitoring.  
MOVE IT  
[CONTACT_111607] (Co -I), Chief of the Section of Hospi[INVESTIGATOR_111493], is the Principal Investigator [INVESTIGATOR_111460], Outcomes, and Validated Experiences Incentive 
Trial, or MOVE IT. [CONTACT_111608] will oversee recruitment in the inpatient hospi[INVESTIGATOR_111461] -
RETAIN partnership, in collaboration with Drs. Patel (Co -I) and Halpern.  
[CONTACT_111609]  (Co -I) is an Assistant Professor of Medicine and Health Care Management at the Per elman 
School of Medicine and The Wharton School at the University of Pennsylvania is the Co -Investigator for the 
Mobility, Outcomes, and Validated Experiences Incentive Trial, or MOVE IT.   
 
c. Participating Parent Trial Sites  
 
The RETAIN trial will be conducted at two sites participating in the BASC parent trial, Northwestern 
University and the University of Pennsylvania; and one site participation in the MOVE IT parent trial, the 
Hospi[INVESTIGATOR_71971]. Thes e institutions are imbued with substantial research 
infrastructures and offer close proximity of site PIs to the clinics from which patients will be recruited. Each 
parent trial supports research staff; in collaboration with the Site PIs, the parent trial research staff will 
carry out the protocol at their respective institutions.    Parent Trial  Site Name  [CONTACT_111596], IL [ZIP_CODE]  
The University of Pennsylvania  Philadelphia, PA  [ZIP_CODE]  
MOVE IT   The Hospi[INVESTIGATOR_111462], PA  [ZIP_CODE]  
 
 
 
65 
 5. Study Design  
This study is a prospective randomized controlled trial nested within two randomized controlled trials.   
 
a. BASC Schema  
 

 
 
 
66 
 b. MOVE IT Schema  
 

 
 
 
67 
 c. Key Study Design Elements across Parent Trials  
 
Key elements in study design across thetwo parent trials are highlighted in the table and figure below.  
 BASC  MOVE IT  
Is there a separate step 
to screen for RETAIN-
specific eligibility?  
   
Please see Section 8.b.  
Eligibility.  
 Yes 
 Patients will be probed for 
prior knowledge of 
incentive randomization, equalization, or the maximum amount offered 
under RETAIN.  
 No 
 
 
Do patients actively 
consent to the RETAIN 
trial?  
 
 
 
Please see Section 8.d.   
 No 
 A waiver of consent for 
RETAIN has been approved by [CONTACT_1201].  No 
 
A waiver of consent for 
RETAIN has been approved by [CONTACT_1201].  
Can anyone enroll in 
the parent trial without enrolling in RETAIN?  
 Yes, if they screen 
ineligible specifically for 
RETAIN  No 
Incentive for parent 
trial subjects not enrolled in RETAIN  
 
Please see Section 6.d.  
Subject Remuneration.  
 $200  Not applicable  
Incentive levels  
 
Please see Section 7. 
Randomization.  Low:  $0  
Middle:  $200  
High:  $500  Low:  $0 
Middle:  $100  
High:  $[ADDRESS_124219] Remuneration.  $300 in two $150 
insta llments, plus up to $300 in two $150 
installments  
  
 
 
 
 
68 
 $200 from individual 
session/travel payments.[ADDRESS_124220] before participants’ first in -person or “intake” visit with BASC research staff. This 
phone assessment, which reduces the likelihood that BASC participants will attend an intake session only to learn that they are ineligible, is a pre -screening encounter  during which participants first learn 
basic details of the BASC trial. If eligible for RETAIN, they will be randomized and complete the first set 
of RETAIN assessments over the phone.  RETA IN assessments will take 10 additional minutes during the 
initial phone e ligibility call (see Section 8.f.  Administration of Survey Instruments).   
Participants who pass the BASC pre -screening on the phone will schedule a baseline intake visit. During 
the baseline intake visit, RETAIN assessments, including the BASC consent process, will constitute [ADDRESS_124221] visit once enrolled on the study; during this call, all RETAIN -randomized, BASC -consented patients 
will be debriefed and learn of the payment procedures. The debriefing process will take [ADDRESS_124222]’s participation time in the 
study will exceed two hours.  
ii. MOVE IT  
 
RETAIN procedures will commence during clinical research coordinators’ initial encounter with patients 
on the hospi[INVESTIGATOR_111494]. The clinical research coordinator will administer all RETAIN assessments in one 
encounter (see Section 8.f.  Administration of Survey Instruments).  Study participants will spend 
approximately 30 -75 minutes of their time to complete the questionnaires  and the MOVE IT consent 
process. Following consent, participants will be debriefed and compensation will be arranged during the 
same encounter. We anticipate that the debriefing and payment process will take approximately 20 -25 
                                                           
2 The high- level incentive arm in the BASC -RETAIN study is $500. This amount accounts for a $200 payment for time, effort, and 
travel paid for by [CONTACT_111526], which existed prior to partnering with the RETAIN  study , as well as $[ADDRESS_124223]’s participation time in the study will exceed 
two hours.  
6. Subject Recruitment  
 
Recruitment for the RETAIN study is intricately linked to recruitment for the parent RCTs. No 
recruitment efforts outside the parent trials’ efforts will occur. Specific measures will be taken to ensure 
that patients who are exposed to RETAIN procedures by [CONTACT_72683] -of-mouth (and BASC) or during their 
inpatient stay (MOVE IT) are screened out or not approached for the RETAIN study.  
a. Accrual  
 
During the  44-month period of the  trial, we plan to enroll 576 patients in RETAIN in association with 
each parent  trial. If this goal is achieved, there would be a total of roughly 1,778 patients in RETAIN 
overall, but RETAIN data associated with each of the 2 parent trials will be analyzed separately. Within 
each parent trial, we anticipate that 50% of RETAIN patients (288 of 576) will choose to enroll in the parent trial. However, we recognize that the total sample sizes and consent rates may vary across the 2 
pare nt trials associated with RETAIN.   
b. Key inclusion criteria  
 The eligibility criteria are:  
 
1) Eligible for parent trial  
2) 18 years or older  3) Speaks English  
c. Key exclusion criteria  
 
In the BASC partnership, prior knowledge of the incentive randomization or payment equalization used 
for this trial, which will be assessed with open -ended prompts during the first encounter, is an exclusion 
criterion.  
 
We will not assess for prior knowle dge in the inpatient MOVE IT study population. However, only one 
patient per room will be approached for the MOVE IT study to protect against contamination.  
d. Subject remuneration  
 
i. BASC  
 Prospective participants who are not eligible, randomized, and enrolle d in RETAIN but consent to the 
BASC parent trial receive $200 in time, effort, and travel payments. Participants who are eligible, 
 
 
 
70 
 randomized, and enrolled in RETAIN and consent to the BASC parent trial will receive a total of $500 
(see Section 8.d.  Inform ed Consent for RETAIN in BASC and MOVE  IT and Section 8.g.  Parent Trial 
Informed Consent); $300 of this payment derives from the RETAIN incentive payment, while $[ADDRESS_124224] payment ($150) as soon as possible after debriefing, during their first in -person visit on trial (Pre -Quit 1). They will receive the second 
payment ($150) during their final week of treatment for the BASC trial (Week 27). Participants who are 
taken off the BASC study for medical reasons will receive full compensation. If participants withdraw from the study for personal reasons, they will not receive the second payment.  
ii. MOVE IT  
 
Patients who are not eligible for MOVE IT will not be paid. Participants who are eligible for MOVE IT, 
enrolled in RETAIN, and consent to the study will receive the payment in t wo installments (see Section 
8.d. Informed Consent for RETAIN in BASC and MOVE IT).  They will receive the first payment ($150) as 
soon as possible after debriefing; they will receive the second payment ($150) during their final week of 
participation (week 13). Participants who are taken off the MOVE IT study for medical reasons will 
rece ive full compensation. If patients withdraw from the study for personal reasons, they will not 
receive the second payment.  
e. Payment Equalization  
 During the debriefing session, the parent trial staff will explain that all RETAIN - and parent trial- enrolled 
participants will receive the full high -level incentive paymen t ($300 in BASC (see Section 6.d. ), and $300 
in MOVE IT) in two installments. Such payment equalization is necessary because it promotes fairness 
by [CONTACT_111566].  
7. Randomization  
a. Groups  
 
Subjects enrolled in RETAIN will be randomized into three groups. Depending on which group they’ve been assigned, subjects will be presented with one of three parent trial consent forms in both electronic 
and paper formats (see Section 8 Study Procedures).  The parent trial consent forms will display three 
different incentive amounts (low -, middle -, or high -level incentive). Consent 1 (low- level incentive arm) 
will include a paragraph on the first page that will briefly state what the study is about and indicate to patients that participation in the study is voluntary and patients will not be paid if they choose to 
participate. The consent form will indicate that participants will not be paid under the standard section, 
“Will I be paid for taking part in this  study?” Consents 2 (middle -level incentive arm) and 3 (high -level 
incentive arm) will include a paragraph on the first page that will briefly state what the study is about 
and indicate that participation is voluntary and patients will be paid the incentiv e (middle - or high -level) 
if they choose to participate. The consent form will also include payment information under the 
 
 
 
[ADDRESS_124225] section, “Will I be paid for taking part in this study?” that describes the level. Consents [ADDRESS_124226] section (BASC). During debriefing, all participants enrolled in RETAIN and their 
respective parent trials will learn of their assignment to one of three groups.  
b. Assignment  
 
Participants will be randomized to the 3 experimental arms (low -, middle -, and high -level incentive) in 
equal, 33.3% probabilities. A Penn analyst will implement block randomization stratified by [CONTACT_111567]. The trial’s primary 
statistician on the Penn research staff will provide a block randomization scheme for each clinical 
research coordinator (MOVE IT) and will upload a CSV file to the REDCap rand omization module. He/she 
will also provide a block randomization scheme for each site for the Access Data Manageme nt System 
(BASC) (see Section 10 .a.1. Data Management – BASC). The parent trial research staff will respond to 
initial eligibility prompts n t he REDCap software through an initialization step and will immediately 
receive the randomization assignment for that participant. Randomization will take place in the DMS for 
the BASC trial. This will allow them to message to the participant the appropriat e incentive level for 
participation in the parent trial, and present  the correct paper consent  based on their arm assignment (see Sections 8.g.  Parent Trial Informed Consent).  
i. BASC  
 
Randomization and group assignment occurs after pre -screening data are collected and RETAIN 
eligibility probes are administered on the eligibility pre -screening call for the BA SC parent trial (see 
Section 8.e.2 Administration of Survey Instruments – BASC). Research staff will know group assignment 
when patients are first intr oduced to the BASC trial on the phone in order to message the assigned 
payment ($0, $200, $500) for the participant. Participants who are deemed preliminarily eligible will 
schedule an intake session, where they will view the electronic BASC parent trial c onsent form ($0, 
$200, or $500) and receive a paper copy of the form with respective incentive information.  
ii. MOVE IT  
 
Randomization and group assignment occur after MOVE IT screening steps (see Section 8.e.3 
Administration of Survey Instruments –  MOVE IT) following clinical research coordinators’ brief 
introduction to the study upon entering patients’ hospi[INVESTIGATOR_39223]. Clinical research coordinators will 
randomize patients and know the group assignment as they complete the recruitment script and assess 
patient s’ interest in learning about the MOVE IT trial. Assignment occurs prior to registering the patient 
in the Way to Health platform used for survey administration.  
 
 
 
 
 
[ADDRESS_124227] until labs are 
conducted at the baseline intake session, following participants’ signature [CONTACT_111595]. However, initial eligibility screening on the  pre- screen eligibility call will enable the BASC research 
team to determine which participants may be assessed for RETAIN eligibility.  
In the MOVE IT study, clinical research coordinators will pre - screen participants for parent trial 
eligibility prior t o the initial approach on the inpatient wards. However, final eligibility determination 
will take place immediately after coordinators’ initial approach once smartphone ownership and 
patients’ participation status in other physical activity trials is ascer tained .  
 
a. Eligibility  
 
Using methods employed by [CONTACT_976] [INVESTIGATOR_111466],29,30,64 parent trial research staff w ill use 
prompts to assess participants’ prior knowledge about the RETAIN study in the BASC study. Prompts will 
not be used in the MOVE IT study, as we do not anticipate contamination among patients on the 
general medicine and oncology wards of the hospi[INVESTIGATOR_307]; no two patients will be approached in the same 
room at once; and readmitted patients will not be re -approached.  
 
b. Inclusion of Women and Minorities  
   
No participants will be excluded from study participation based on gender, race, or ethnicity. We 
expec t that enrollment of participants from The University of Pennsylvania Perelman Center for 
Advanced Medicine, Northwestern University out -patient clinics and the Hospi[INVESTIGATOR_111495] t hat closely reflect the underlying 
outpatient populations at these facilities in terms of gender, race, and ethnicity. These populations are 
also reflective of the broader populations of the Philadelphia, Chicago, Houston, St. Louis, and [LOCATION_011] 
metropolita n areas.  
 
c. Informed Consent for RETAIN in BASC and MOVE IT  
 
The sole informed consent processes used in both BASC and MOVE IT will be for the parent trials (see 
Section 8.f  Parent Trial Informed Consent). Randomization and enrollment to RETAIN in the BASC a nd 
 
 
 
[ADDRESS_124228].  BASC participants deemed eligible for BASC via phone pre -screening and 
RETAIN. MOVE IT participants will be randomized imme diately after eligibility sc reening in their hospi[INVESTIGATOR_111496].  
 
All participants who are randomized and enrolled in  RETAIN and consent to the BASC and MOVE IT will be debriefed on the randomization of incentives and the purpose of the RETAIN study wil l be explained 
(see Sections 8.g. and 8.h.  Debriefing in BASC and MOVE IT, respectively).  
d. Administration of Survey Instruments  
i. BASC  
 Procedures for this study will commence during initial pre -screening eligibility assessment via phone for 
the BASC trial. During this call, all study candidates will complete an initial eligibility assessment with 
research staff members from the clinical site from which they are being re cruited (Northwestern or 
Penn). Research staff will begin with the BASC eligibility screen  survey, which includes basic 
demographic questions, as well as questions related to participants’ endorsement of symptoms of clinical depression. Once a patient is determined to be preliminarily eligible for BASC, the research staff 
will ask the RETAIN el igibility prompt to assess for prior knowledge of the specific incentives or 
randomization used for RETAIN. Participants who do not have prior knowledge of the RETAIN incentives or randomization will be randomized by [CONTACT_111568]’s  Data Managem ent System 
(DMS) (see Section 10 .a.1 Data Collection and Data Confidentiality –  BASC). Prospective participants will 
then be introduced to BASC study basics and risks and informed that if they are determined to be eligible for the BASC study and participate in the BASC trial, they will receive $0, $200, or $[ADDRESS_124229] study information regarding session and travel compensation for the BASC trial 
without RETAIN messaging. For information on remuneration in  the BASC trial, see Section 6.d . These 
participants will not be debriefed or paid the RETAIN incentives.  
 
Before research staff finalize logistical details on the BASC study and schedule intakes for tentatively 
eligible patients, they will administer several RETAIN -related questionnaires to assess 1) demographics 
and personal financial well- being, 2) attitudes towards biomedical research, 3) prior experience in 
research, and 4) perceptions of research risk. The screener will administer these surveys via phone using 
CRF forms adopted for the RETAIN trial that will lat er be scanned into the BASC trial’s DMS.  
 
Participants who pass the BASC pre-screening will be scheduled  to attend a 2 -3½ hour Intake session for 
the BASC trial. During the intake session, BASC research staff at Penn and Northwestern will read a pre -
BASC c onsent script before presenting an electronic image of the BASC informed consent/ HIPAA forms 
with additional information regarding the RETAIN incentive randomization condition; this electronic 
 
 
 
74 
 image will be p resented via tablet or desktop . By [CONTACT_1601] t he BASC consent with randomized 
compensation information electronically, we will assess the amount of time participants spend reading 
each part of the main trial consent form. Each section (e.g., Study Introduction, Procedures by [CONTACT_4838], 
Possible Risks and Discomforts, etc.) will be presented as a survey in REDCap. Time -stamp data collected 
for this REDCap module will be linked by [CONTACT_111569]’ telephone  pre-screen call (see Section 10 .a.1.  Data  Collection and Data 
Confidentiality - BASC).  
 Once participants finish reading and before signing a paper version of the BASC trial consent, they will 
complete brief assessments of perceptions of research risk (administered over the telephone pre- screen 
and a gain at intake –  see Section 9.a.  BASC Study Calendar). They will also complete assessments on 
perceptions of the difference between research and individualized patient care and understanding of 
the smoking cessation study via a trial elements quiz. Al l of these measures will be administered via the 
CRF paper and pencil processes currently used in the BASC trial. The responses to the quiz will be 
reviewed with participants, during which participants’ questions will be answered.   
 
ii. MOVE IT  
 Clinical rese arch coordinators will identify patients through electronic health record -based screening for 
the MOVE IT study and preliminarily eligible patients will be approached for recruitment in their 
hospi[INVESTIGATOR_60916].  
 
Using a recruitment script in REDCap, clinical research coordinators will describe a study that aims to help patients improve their mobility and prevent them from needing to return to the hospi[INVESTIGATOR_307].  The 
REDCap -hosted MOVE IT recruitment script will prompt the clinical research coordinator to assess for  
patient’s eligibility in the MOVE IT study t hrough two screening questions . Eligible patients will be 
randomized in real time to one of three incentives for participation ($0, $100, or $300). The clinical 
research coordinator will finish reading the recru itment script, indicating the amount participants will 
be paid for the MOVE IT  Trial. Ineligible patients will not be randomized or enrolled on the RETAIN trial.  
 For patients  who are interested in learning more about the MOVE IT study, the MOVE IT clinica l 
research coordinators will proceed to register the participant in the Way to Health platform and 
administer the tools in Way to Health via tablet ( see Section 1 0.a.3. Data Management - MOVE IT ). The 
patient  will be asked to complete several short  question naires : 1) demographics, 2) personal financial 
well- being, 2) attitudes towards biomedical research, and 3) prior experience in research.  
 
Once the patient has completed aforementioned tools in Way to Health, the clinical research 
coordinator will return to the REDCap database and read  a pre -consent introductio n script  before  
presenting the an electronic image of the MOVE IT informed consent/ HIPAA forms with additional 
information regarding the RETAIN incentive randomization condition. By [CONTACT_111537], we will assess the amount of time 
 
 
 
[ADDRESS_124230] to Health  platform on a tablet . The responses to the quiz will be reviewed with participants, 
during which participants’ questions will be answered.   
 
e. Parent Trial Informed Consent ( BASC, and MOVE IT )  
 
Parent trial research staff will present the paper consent in conjunction with their review of any questions  generated by [CONTACT_111570], REDCap -hosted images of 
the consent form . Next,  prospective participants will be asked to either provide consent or decline 
participation in the parent t rials. The research staff  will then facilitate participants’ completion of the 
final two surveys (perceived coercion and prior persuasion questions) .  All participants –  no matter their 
decision – will be asked to complete these two post- consent surveys.  
 In the BASC and MOVE IT studies, participants who decline consent may seek participation in other 
trials for smoking cessation or physical activity, respectively.  
  
 
f. Debriefing in BASC  
 
Participants  will be debriefed following their intake eligibility visit once they have signed consent, and 
they are determined to be fully eligible for the BASC trial. Debriefing will take place on the reminder call 
before participants’ first scheduled visit on trial,  called “Pre -Quit 1.”  The same pr ocesses described in 
Section 8.g . will be used to inform patients of the RETAIN study procedures and process payment per 
institutional standard. Debriefing in MOVE IT  
 
Participants will be debriefed during the same encount er in which they are approached. The same 
processes described in Section 8.g. will be  used to inform patients of the RETAIN study procedures and 
process payment per institutional standard.  
 
 
 
 
[ADDRESS_124231] in which information regarding the 
random allocation of incentive levels is necessarily withheld during the consent processes. The following 
justifications support the research team’s use of incomplete disclosure in the RETAIN trial:  
 
The use of incomplete disclosure in this study is grounded in the trial’s status as minimal risk.  
 
The RETAIN  study involves no more than minimal risk to participants for 5 reasons: (1) incentives in the 
amounts we are proposing are given to patient subjects as part of many ongoing or completed trials;35 
(2) the evidence  available to date suggests that the ethical concerns identified with incentives may not 
arise, (3) we have established robust procedures  for monitoring whether those ethical concerns do in 
fact arise and for stoppi[INVESTIGATOR_111469], (4) the patients would be approached to participate in the parent RCT s without the incentive study, and (5) their participation in the RETAIN 
study  will not affect which treatment they receive in the parent RCT s. 
 
To the extent that it is avoidable, the use of deception will have no adverse effects on welfare, and all 
adverse effects will be minimized.  
 
Adverse events from the incomplete disclosure o f the randomization of participants to different levels 
of incentives will be minimized through the debriefing process. Patients will be debriefed following their 
decision to enroll in the parent trial immediately before their first treatment visit (BASC)and within the 
same session as the initial approach (MOVE IT). This debriefing will therefore happen within a few days  
(at maximum)  of the deception, and will provide participants with full disclosure of the research and 
with an opportunity to withdraw thei r participation or their data. Patients who decline to participate in 
the parent trials will not be debriefed. The Principal Investigator [INVESTIGATOR_111497].  
 
Additional oversight will be provided by [CONTACT_716]: (1) a DSMB that will have the flexibility to adjudicate trial continuation or cessation based on a compendium of outcomes data; (2) two advisory 
boards comprised of experts in relevant disciplines including research ethics and regulations that will 
assist the investigators in addressing any unforeseen ethical and scientific issues during the trial’s 
conduct.  
 
The value of the study is sufficient to warrant waiving som e aspects of the requirement for full 
disclosure in the informed consent process.  
 
While our study does not provide participants with untrue information and thus does not technically qualify as deception research, it remains necessary for parent trial research staff to withhold 
information regarding the random assignment of incentive levels during the incentives trial consent 
process. This RCT will provide important information about the impact of financial incentives on 
 
 
 
[ADDRESS_124232] of 
future human research subjects by [CONTACT_111571], and whether reasonable but uncertain 
ethical concerns arise when offering different levels of incentives. In short, the present variability in IRB 
practices regarding incentive use means, by [CONTACT_108], that either (a) incentives are being underutilized, creating inefficiencies, potentially sacrificing study completion, and thereby [CONTACT_111541]; or (b) incentives are being over-
utilized, creating threats to autonomous choice or targeting a “research underclass”. The current trial is 
necessary to improve upon this worrisome status quo, and henc e has the potential to make the entire 
practice of clinical trials more ethical.  
 
There is no alternative to address the scientific question in a valid manner but to use 
deception/incomplete disclosure.  
 
It would not be feasible to address the aims of the  study in the context of a real RCT ( BASC, and MOVE 
IT) without the incomplete disclosure related to the random assignment of financial incentives. Indeed, 
any disclosure about the random assignment of incentives would thwart the ability to measure either the intended or the potential unintended consequences of research incentives. To definitively address the ethics, effectiveness, and cost effectiveness of incentives for research participation, high -quality 
evidence is needed, and to date, studies of incen tives to participate in hypothetical RCTs of common 
interventions, as well as small studies in non -generalizable cohorts, do not fully answer whether the 
ethical concerns of financial incentives actually manifest.  
 
Subjects cannot be informed prospectively  of the use of deception/incomplete disclosure and consent 
to its use.  
 
Prospectively informing patients in even a general way would sabotage the goals of the research because it would create a cognitive state (decision -making context) that is fundamentall y different from 
that which future patients encountering future incentives would have at corresponding times. Because 
this trial is fundamentally about choices made by [CONTACT_111542], and how risks and 
incentives might modify those choic es, any extraneous factors that could also modify decisions or 
choices must be avoided. Following the debriefing, all eligible patients will be given the opportunity to 
ask any questions regarding the incentives study. The parent trial nurse/staff will then explain that all 
participants actually will receive the full $1,200 payment and he or she will detail the plans for disbursement.  
9. Study Calendar s 
 
 
 
 
78 
 The following calendar reflects the procedures as they are described in Section 8.  
i. BASC Study Calendar  
 
Study  calendar for RETAIN and Behavioral Activation and Varenicline for Smoking Cessation in 
Depressed Smokers.  
Week  0P 0c 0p 1c 27P 
Screening and Eligibility ( BASC ) X X    
RETAIN Eligibility Prompts       
Demographics  X  
   
Economic Well -Being  X  
   
Research Attitudes 
Questionnaire  X  
   
Prior Research Experience  X  
   
Compared Riskiness Scale  X     
Informed Consent 
Administration ( BASC  Trial)   X     
Compared Riskiness Scale   X     
Therapeutic Misconceptions   X    
Trial Elements Quiz   X     
Review answers + Patient Q &A   X     
Informed Consent Signing ( BASC  
Trial consent)   X     
Perceived Coercion and Prior 
Persuasion Question   X    
Debriefing    X        
Payment     X 
[First 
Installment of 
150 disbursed as 
soon as possible 
after debriefing]  X 
[Second 
Installment of 
150 
disbursed 
during final 
week of 
treatment]  
 P= phone  
C=clinic visit (in -person session)  
 
ii. MOVE IT Study Calendar  
 
Study calendar for RETAIN and Mobility, Outcomes, and Validated Experience s Incentive Trial (MOVE 
IT).  
Week  0c 1c 13M 
Screening and Eligibility  X   
Demographics  X   
 
 
 
79 
 Economic Well -Being  X   
Research Attitudes 
Questionnaire  X   
Previous Research Experience  X   
Informed Consent 
Administration (MOVE IT Trial)  X    
Compared Riskiness Scale  X    
Therapeutic Misconceptions  X   
Trial Elements Quiz  X    
Review answers + Patient Q 
&A X    
Informed Consent Signing 
(MOVE IT Trial consent)  X    
Perceived Coercion and Prior 
Persuasion Question  X   
Debriefing  X        
Payment   X 
[First Installment of 
150 disbursed as soon 
as possible after 
debriefing]  X 
[Second Installment of 150  
disbursed during final 
week of intervention]  
 P= phone  
C=clinic visit (in -person session)  
M=Mail – no visit or call  
 
10.  Data Management  
a. Data Collection and Data Confidentiality  
 
Prudent steps will be taken to ensure that all information will be kept confidential and secure, including 
medical and survey data as well as social security numbers. Unique patient identifiers will be assigned to each  subject locally.  
i. BASC  
 
Survey data will be collected via phone and in -person using a Case Report Form format for the RETAIN -
BASC  partnership. The BASC  Penn database manager will oversee the database management system 
(DMS ) for this trial.  The DMS is  an MS Access database that permits real -time data entry, storage, and 
QA by [CONTACT_111545], which increase standardization across 
 
 
 
[ADDRESS_124233] accidental corruption or deletion.  The 
Penn BASC research staff will compare 100% of hard copy to computer data. Protection of participant 
privacy is accomplished by [CONTACT_111546] , use of ID numbers rather than 
participant names, keepi[INVESTIGATOR_111471], and strictly limiting access to the dataset that links 
participant names with ID numbers.  
 
Every touchpoint with participants is “milestoned ” (e.g., attended, missed, scheduled) in the trial 
database to ensure subject tracking through the trial. The RETAIN team will work with the BASC  study 
team to ensure all RETAIN -relevant screening outcomes are adequately milestoned within the DMS.  
 
For mea sures of time spent reading the BASC  parent trial consent form, BASC research staff will use 
REDCap at the eligibility intake session. BASC  research staff will enter the subject and contact [CONTACT_111572].  
ii. MOVE IT  
 
Survey data will be collected via Qualtrics on the Way to Health platform for the MOVE IT partnership. 
Penn Medicine Academic Computing Services (PMACS) supports  the computing infrastructure that will 
be used for  the MOVE IT study , including the Way to Health web portal. PMACS is a joint effort of the 
University of Pennsylvania's Abramson Cancer Center, the Cardiovascular Institute, the Department of 
Pathology, and the Leonard Davis Institute. PMACS provides a secure computing environment for a 
large volume of highly sensitive data, including clinical, genetic, socioeconomic, and financial 
information. PMACS requires all users of data or applications on PMACS servers to complete a PMACS -
hosted cybersecurity awareness course annually, which stresses  federal data security policies under 
data use agreements with the university. The curriculum includes Health Insurance Portability and Accountability Act (HIPAA) training and covers secure data transfer, passwords, computer security 
habits and knowledge o f what constitutes misuse or inappropriate use of the server. All investigators 
and research staff with direct access to the identifiable data will be required to undergo annual 
responsible conduct of research, cybersecurity, and HIPAA certification in acc ordance with University of 
Pennsylvania regulations.  
 
All data will be stored and analyzed on institutionally managed and secured servers with access 
privileges limited to those with a need to know via the use of single -user access passwords and 
usernames . All study personnel that will use this data are listed on the IRB application and have 
completed training in HIPAA standards and human subjects research. Whenever possible, direct 
identifiers will be removed from analysis files.  
 
 
 
 
[ADDRESS_124234] confidentiality. An investigator or statistician who logs in will be able to 
download only de - identified data. Parent trial research staff at the different sites will not be able to 
access information from other sites; we will put in place data user groups in the REDCap system. Only 
parent trial research staff responsible for contact[CONTACT_111547] -up meetings or responding 
to questions about the study will be able to view participant names and contact i nformation. This 
personal information will be used to contact [CONTACT_111548], payments, or they contact [CONTACT_111549] a problem. We will implement multiple, redundant protective 
measures to guarantee the privacy and security  of the participant data. All study data will be stored on 
the secure/firewalled servers at the University of Pennsylvania. These data servers are maintained in a 
guarded facility behind several locked doors, with very limited physical access rights. They are also 
cyber -protected by [CONTACT_111550]. Electronic 
access rights are carefully controlled by [CONTACT_111551]. We believe this multi- layer system of 
data security, identical to the system protec ting the University of Pennsylvania Health Systems medical 
records, greatly minimizes the risk of loss of privacy.  
c. Subject Privac y 
 
We will collect subjects' names, addresses, phone numbers, and data required for the completion of W -
[ADDRESS_124235], we will develop and implement 
methods of verifying entered data and of quality control among parent trial research staff who will be 
directly entering data into the REDCap system. Second, the PI [INVESTIGATOR_111472], protocol deviations/violations and unanticipated events to the 
IRBs and funding agency promptly, as appropriate. The PI [INVESTIGATOR_111473], accru al 
rates, retention rates, and all other logistical issues to the DSMB at least biannually (if there are serious 
adverse events occur at any time that the investigators feel ought to be brought to the attention of the 
DSMB sooner, the DSMB can also meet on  an ad hoc basis). Third, there will be a DSMB responsible for 
monitoring the trial, convening for the first time in December [ADDRESS_124236]  includes the following members:  
Jennifer S. Blumenthal -Barby, PhD  (Chair) : expertise in ethical contexts of human judgment and decision -
making in human research.    
Salma Jabbour, MD : expertise in radiation oncology with a subspecialty in lung cancer.  
Brenda F. Kurland, PhD : expertise in biostatistics with research emphasis on longitudinal and other 
correlated data.  
Jeffrey M. Peppercorn, MD, MPH : expertise in medical oncology with research emphasis on bioethics 
and health policy, as well as cancer surv ivorship.  
Kim Vernick : member of th e University of Pennsylvania’s Proton Patient Alumni Program , Patient and 
Family Advisory Council, and a cancer survivor .  
The PI  (Scott Halpern) , assisted by [CONTACT_74143], will be responsible for maintaining 
communication between the DSMB and the individual project staff.  The DSMB will be responsible for 
monitoring the trial and making decisions about the termination of individual study arms or the study 
itself. The DSMB will review and approve the research protocol. They will also assess the progress of the 
trial, including the assessment of data quality, participant recruitment, accrual and retention, participant 
risk versus benefit, and study outcomes.  Corresponding recommendations will be issued at all 
subsequent meetings. These recommendations will be based on the results and discussion of interim 
analyses, conducted at one -half, and three -fourths of the target same size. DSMB recommen dations may 
be guided by [CONTACT_111573]. The DSMB may recommend permanent suspension of 
enrollment, or temporary suspension pending protocol modification. Following each meeting, and the 
provision of recommendations and the response from  the research team, the Principal Investigator [INVESTIGATOR_111474]. Prior to submission to these IRBs, 
the progress reports will be approved by [CONTACT_2020].  
 
 
 
[ADDRESS_124237]. Alisa Stephens -Shields, has 
identified TWO trial stoppi[INVESTIGATOR_004].  The DSMB approved these stoppi[INVESTIGATOR_111498]:  
1. Early evidence of undue inducement that distorts voluntary informed consent. To detect 
whether incentives represent undue inducement, the research team will test the statistical 
interaction between incentive size and risk per ception on the outcome of enrollment in the 
parent RCT. A statistically significant interaction, in the direction that risk perception is less 
strongly associated with enrollment in higher- payment arms, would be grounds for terminating 
the trial or suspend ing a trial arm.  
 2. Early evidence of unjust inducement by [CONTACT_111574] (a) lower income, or (b) reduced financial well- being. Two interaction 
terms will be evaluated in separate models to avoid collinearity. Unjust inducement will be defined as a statistically significant interaction between (a) incentive size and annual household 
income, or (b) between incentive size and economic well -being, each on the outcome of trial 
enrollment. One or both of th ese interactions, if statistically significant in the direction that 
lower -income persons or persons with reduced economic well -being are more strongly 
motivated to participate by [CONTACT_111575], will be considered grounds for 
terminating the trial or suspending a trial arm.  
 
During the trial we will conduct two interim tests of these interactions to evaluate evidence of undue or 
unjust inducement.  In contrast to the final analyses, which will be structured as tests of non -inferiority, 
the interim analyses will be conducted as  superiority tests of the interactions, such that rejection of the 
null hypothesis indicates evidence of the presence of an interaction between incentive size and one of our 
three primary covariates. The interim tests will be conducted after 50% and 75% of  the data have accrued 
within both BASC and MOVE IT and use [ADDRESS_124238] inducement.  
 
The DSMB may also wish to consider increased rates of therapeutic misconception as grounds for early 
termination of the trial. The research team will compare responses to the trial’s measure of the construct 
of therapeutic misconception across the three tria l arms. While no pre -specified statistical monitoring 
guidelines are proposed for this measure, DSMB members may consult with [CONTACT_111610], with whom the 
therapeutic misconception tool for the trial has been developed, for guidance on interpretation of th e data 
provided in the open statistical report.  
d.  Adverse Events  
 
 
 
 
84 
 As this is a minimal risk study, we do not anticipate adverse events; however, we will report all adverse 
events to the Data and Safety Monitoring Board.  
e. Clinicaltrials.gov  
 
The RETAIN trial has been registered on clinicaltrials.gov ([STUDY_ID_REMOVED]). The study profile will be regularly 
updated on the website and summary results uploaded to make information about the study publicly available and promote transparency.  
12. Human Subjec ts Protection  
a. Potential Study Risks  
 
A primary risk to this study is that financial incentives either unfairly induce  participants to participate in a 
trial that they would not otherwise participate in. This is a primary question of this trial. We will convene 
a data and safety monitoring board (DSMB) in conjunction with NIH to monitor any indication that this is 
occurri ng. Our hypothesis is that no population will be unfairly manipulated into participating in a trial that 
they would not otherwise, and that financial incentives could lead to participants examining the potential 
risks of a study more closely than they woul d have otherwise.  
Supporting Research  
A study led by [CONTACT_976] [INVESTIGATOR_111477] -I Karlawish assessed 126 hypertensive patients’ willingness to 
participate in RCTs of experimental antihypertensive drugs.7  We used a 3 x 3 within -subjects factorial 
design in which hypertensive patients were administered, in random sequence, 9 hypothetical RCTs which differed in their risk level (10%, 20%, or 30% chance of drug -related adverse events ) and payment 
($100, $1,000, or $2,000 for a 10- week trial). We found that increasing payments motivated greater RCT 
participation, and that increasing risk levels reduced participation levels (p < 0.001 for each). Importantly, patients’ participation rates declined equivalently with increasing risk levels across all 
payment levels studied, and the statistical interaction between risk and payment was not statistically significant (p=0.30).   This shows that patients were equally sensitive to risk despi[INVESTIGATOR_111499], suggesting that research incentives are not undue inducements.   
Furthermore, this study of payments for RCT enrollment,
[ADDRESS_124239] participation study,7 there was an indication that larger 
payments may preferentially motivate wealthier people to participate (payment -by-income interaction 
p=0.09) . The validity of these results is enhanced by [CONTACT_111576] -by-payment interactions if they existed.  
Co-I Volpp and colleagues asked participants to rate the riskiness of a new technology (transcranial 
magnetic stimulation) being tested in RCTs after being told they would receive $25 or $1,000 for trial 
 
 
 
85 
 participation.8 Participants assigned to review the trials offering $1,000 spent more time reading about 
study risks and other research aspects (mean = 3.7 minutes) than did patients assigned to trials offering 
$25 (mean = 1.0 minutes) (p < 0.01). Larger incentives also decreased the odds that participants would 
skip the page of the informed consent form that described study contraindications (p < 0.05). These 
findings suggest that payments alert people to the possibility of risk, and encourage them to learn more 
about th e study.[ADDRESS_124240] of human subjects research more generally. The 
participants will be debriefed about the purpose of  this study and the knowledge to be gained from it.  
c. Risk/Benefit Analysis  
 
In light of the tremendous benefits to public health and individuals developi[INVESTIGATOR_111479], 
as well as our efforts, outlined above, to mitigate all risks associated wi th this study, we believe that this 
study presents a highly favorable risk -benefit ratio for participation.  
d. Protective Measures  
 
The first safeguard for protection of human subjects includes an experienced and well -trained study 
team. [CONTACT_111611] (PI ) is Associate Professor of Medicine, Epi[INVESTIGATOR_623], and Medical Ethics & 
Health Policy at Penn, Director of the Palliative and Advanced Illness Research (PAIR Center, and Deputy 
Director of the Center for Health Incentives and Behavioral Economics (CHIBE) at the Leonard Davis 
Institute of Health Economics. He has considerable expertise in the design, ethics, and recruitment 
barriers of clinical trials, in leading RCTs of financial incentives to modify health behaviors, and in the 
 
 
 
[ADDRESS_124241]. Hitsman’s current collaborations with Penn include the Abramson Can cer Center - sponsored Extended Duration Varenicline for Smoking Among Cancer 
Patients ([STUDY_ID_REMOVED]) and the NCI -sponsored project described in this report, Behavioral Activation 
and Varenicline for Smoking Cessation in Depressed Smokers ([STUDY_ID_REMOVED]) –  both of which involve 
Penn colleague [CONTACT_111606], who has also successfully collaborated with the RETAIN PI [INVESTIGATOR_111480].  Both 
Drs. Hitsman and Schnoll have experience layering social behavioral manipulations onto existing 
smoking cessation studies to address recruitment challenges, as well as research focuses that are 
geared toward the recruitment of vulnerable patients.  
ii.  MOVE IT  
 
Ryan Greysen, MD, MHS, MA, Section Chief of Hospi[INVESTIGATOR_45047], will co -lead the implementation of the 
MOVE IT study at Penn, in  collaboration with Drs. Patel (Co-I) and Halpern. [CONTACT_111608]’s expertise in 
patient -oriented research targeting vulnerable older adults with multiple comordities -- with particular 
focus on improving both hospi[INVESTIGATOR_111481] --will be leveraged to  integrate RETAIN procedures 
in a way that is at once sensitive to the inpatient care environment and scientifically sound. [CONTACT_111608] 
will lead the MOVE IT study protocol with Site PI [INVESTIGATOR_111482], MD, MBA, MS. An expert in digital health 
initiatives to improve health outcomes and change health behaviors, [CONTACT_33749] is well- equipped to 
operationalize the integration of the RETAIN trial into the mobility study at the Hospi[INVESTIGATOR_71972], having significant content expertise in the use  of incentives within a hospi[INVESTIGATOR_111483].   
e. Additional Protective Measures  
 
To guide the ethical and scientific conduct of this study, and to help position the results so that they 
may have maximal impact on future research efficiency and regulation, we ha ve assembled an External 
Advisory Board (EAB) and an Internal Advisory Board (IAB). The External Advisory Board includes: 
Christine Grady, MSN, PhD, Chief of the NIH Clinical Center’s Department of Bioethics and Head of the 
Section on Human Subjects; Scott Kim, MD, PhD, Senior Investigator in the NIH Department of 
Bioethics; Leslie Wolf, JD, MPH, Professor at the Georgia State School of Law’s Center for Law Health 
and Society; Timothy Coetzee, PhD, Chief Advocacy and Research Officer for the National MS 
Foundation; and Barbara Langloss, Patient Advocate and an alumna of Penn’s Proton Therapy Program. 
Our Internal Advisory Board includes: Steven Joffe, MD, MPH, pediatric oncologist and Vice Chair of the 
 
 
 
87 
 Department of Medical Ethics and Health Policy at Penn; Ezekiel Emanuel, MD, PhD, Chair of the 
Department of Medical Ethics and Health Policy at Penn; and David Festinger, PhD, Adjunct Assistant 
Professor of Psychiatry at Penn and Direct of the Treatment Research Institute’s Section on Law and Ethics Research.  
Finally, the debriefing process, delivered by [CONTACT_111577], is an important element of human subject protection and will ensure that patients (1) understand the recruitment for the pare nt 
trial included a study on the effects of incentives on study enrollment; (2) understand they were 
randomized to receive one of three study incentives (3) understand they were not informed about the RETAIN  study to avoid biasing the study results; and (4) understand no further data are to be collected 
as part  of the RETAIN  study and the study will complete as soon as the incentives are disbursed.  
Additional layers of protection for human subjects include the robust informed consent process ( Section 
8.d.), exceptional data security ( Section 10 ), and the empowe red Data Safety and Monitoring Board 
(Section 11) all described in detail in this protocol.  
 
13.  References  
 
1. Halpern SD. Financial Incentives for Research Participation: Empi[INVESTIGATOR_111484], Available Answers 
and the Burden of Further Proof. American Journal of the Medical Sciences. Oct 2011;342(4):290 -
293.  
2. National Institutes of Health Office of Human Subjects Research. Guidelines for remuneration of research subjects in the intramural research program and registration in the clinical research volunteer program database.  Accessed December 3, 2011 at http://ohsr.od.nih.gov/info/pdf/InfoSheet20.pdf
. 
3. Macklin R. 'Due' and 'undue' inducements: On paying money to research subjects. IRB: a review of human subjects research. 1981;3(5):[ADDRESS_124242] to payment? JAMA. 1997;278:199 -200.  
5. McNe il P. Paying people to participate in research: why not? Bioethics. 1997;11:390 -396.  
6. Bentley JP, Thacker PG. The influence of risk and monetary payment on the research participation decision making process. J Med Ethics. June 1, 2004 2004;30(3):293- 298.  
7. Halpern SD, Karlawish JHT, Casarett D, Berlin JA, Asch DA. Empi[INVESTIGATOR_111485]. Archives of Internal Medicine. 2004;164:801 -803.  
8. Cryder C, London AJ, Volpp KG, Loewenstein G. Informative Inducement:  Study Payment as a Signal of Risk. Social Science & Medicine. 2010;70(3):455- 464.  
9. Altman DG. Statistics and ethics in medical research III: How large a sample? Br Med J. 1980;281:[ADDRESS_124243] those who serve. New England Journal of Medicine. 2000;343:1643 -
1645.  
11. Ellenberg SS. Randomization designs in comparative clinical trials. N Engl J Med. 1984;310(21):1404 -
1408.  
12. Freiman JA, Chalmers TC, Smith H, Jr, Kuebler RR. The importance of beta, the type II error and sample size in the design and interpretation of the randomized controlled trial: survey of 71 "negative" trials. N Engl J Med. 1978;299:690 -694.  
13. Meinert CL.  Clinical trials: Design, conduct, and analysis. [LOCATION_001]: Oxford University Press; 1986.  
 
 
 
[ADDRESS_124244] century: 
Reinvigorating the NCI Cooperative Group Program.  Washington, D.C. : The National Academies 
Press; 2010.  
15. Freedman B. Scientific value and validity as ethical requirements for research: A proposed 
explication. IRB: Rev Hum Subjects Res. 1987;9(6)):[ADDRESS_124245] of underpowered clinical 
trials. JAMA. 2002;288:358 -362.  
17. Kramer MS, Shapi[INVESTIGATOR_111486]. Scientific challenges in the application of randomized trials. JAMA. 1984;252(19):2739- 2745.  
18. Nathan RA. How important is patient recruitment in performing clin ical trials? Journal of Asthma. 
1999;36(3):213 -216.  
19. Hunningshake DB, Darby [CONTACT_28474], Probstfield JL. Recruitment experience in clinical trials: Literature summary and annotated bibliography. Controlled Clinical Trials. 1987;8:6S -30S.  
20. Probstfield JL, Witt es JT, Hunningshake DB. Recruitment in the NHLBI population -based studies and 
randomized clinical trials: data analysis and survey results. Controlled Clinical Trials. 1987;8:141S -
149S.  
21. Vollmer VM, Osborn ML, Hertert S, et al. Recruiting hard -to-reach subjects: Is it worth the effort? 
Controlled Clinical Trials. 1994;15:154 -159.  
22. Emanuel EJ, Schnipper LE, Kamin DY, Levinson J, Lichter AS. The costs of conducting clinical 
research. J Clin Oncol. Nov 15 2003;21(22):4145- 4150.  
23. Caldwell PH, Hamilton S, Tan A, Craig JC. Strategies for increasing recruitment to randomised 
controlled trials: systematic review. PLoS Med. 2010;7(11):e1000368.  
24. Donovan J, Mills N, Smith M, et al. Quality improvement report: Improving design and cond uct of 
randomised trials by [CONTACT_111558]: ProtecT (prostate testing for cancer 
and treatment) study. BMJ. October 5, 2002 2002;325(7367):766- 770.  
25. Sugarman J, Kass NE, Goodman SN, Perentesis P, Fernandes P, Faden RR. What patie nts say about 
medical research. IRB: A review of human subjects research. 1998;20(4):1- 7. 
26. Wendler D, Krohmal B, Emanuel EJ, Grady C, Grp E. Why patients continue to participate in clinical research. Archives of Internal Medicine. Jun 23 2008;168(12):1294- 1299.  
27. Halpern SD. Prospective preference assessment: A method to enhance the ethics and efficiency of 
randomized controlled trials. Controlled Clinical Trials. 2002;23:274 -288.  
28. Shah A, Efstathiou JA, Paly JJ, et al. Prospective preference assess ment of patients’ willingness to 
participate in a randomized controlled trial of intensity -modulated radiotherapy versus proton 
therapy for localized prostate cancer. International Journal of Radiation Oncology*Biology*Physics. 
2012;83:E13- E19.  
29. Carroll R, Antigua J, Taichman DB, et al. Pulmonary arterial hypertension patients' willingness to 
participate in randomized clinical trials of novel therapi[INVESTIGATOR_014]. Clinical Trials. 2010;9:348 -357.  
30. Halpern SD, Karlawish JHT, Casarett D, Berlin JA, Townsend RR, As ch DA. Hypertensive patients' 
willingness to participate in placebo -controlled trials: Implications for recruitment efficiency. 
American Heart Journal. 2003;146:985- 992.  
31. Slomka J, McCurdy S, Ratliff EA, Timpson S, Williams ML. Perceptions of financial payment for research participation among african -american drug users in HIV studies. Journal of General Internal 
Medicine. Oct 2007;22(10):1403 -1409.  
32. Stunkel L, Grady C. More than the money: A review of the literature examining healthy volunteer motiva tions. Contemporary Clinical Trials. May 2011;32(3):342 -352.  
33. Dunn LB, Kim DS, Fellows IE, Palmer BW. Worth the risk? Relationship of incentives to risk and benefit perceptions and willingness to participate in schizophrenia research. Schizophr Bull. Ju l 
2009;35(4):730 -737.  
 
 
 
89 
 34. Dickert N, Emmanuel E, Grady C. Paying research subjects: An analysis of current policies. Annals of 
Internal Medicine. 2002;136:368 -373.  
35. Grady C, Dickert N, Jawetz T, Gensler G, Emanuel E. An analysis of U.S. practices of pay ing research 
participants. Contemp Clin Trials. 2005;26:365 -375.  
36. Emanuel EJ. Ending concerns about undue inducement. Journal of Law Medicine & Ethics. Spr 
2004;32(1):100 -105.  
37. Emanuel EJ. Undue inducement: Nonsense on stilts? American Journal of Bioethics. Sep- Oct 
2005;5(5):9- 13. 
38. Emanuel EJ, Currie XE, Herman A. Undue inducement in clinical research in developi[INVESTIGATOR_14696]: is 
it a worry? The Lancet. 2005;366(9482):336- 340.  
39. Hyun I. Fair payment or undue inducement? Nature. 2006;442(7103):629- 630.  
40. Martin R. Undue inducement in clinical research. Lancet. 2005;366(9482):275- 276.  
41. Casarett D, Karlawish JHT, Asch DA. Paying hypertension research subjects. Journal of General 
Internal Medicine. 2002;17:650 -652.  
42. Wilkinson M, Moore A. Inducement in research. Bioethics. 1999;11:373 -389.  
43. Elliott C, Abadie R. Exploiting a research underclass in phase 1 clinical trials. New England Journal of 
Medicine 2008;358:2316 -2317.  
44. Denny CC, Grady C. Clinical research with  economically disadvantaged populations. Journal of 
Medical Ethics. July 1, 2007 2007;33(7):382 -385.  
45. Viens AM. Socio -economic status and inducement to participate. American Journal of Bioethics. 
2001;1(2).  
46. Wertheimer A. Should we worry about money?  Rethinking the ethics of clinical research. [LOCATION_001]: 
Oxford University Press; 2011:117 -190.  
47. Bernstein M. Payment of research subjects involved in clinical trials is unethical. Journal of Neuro -
Oncology. Jul 2003;63(3):223- 224.  
48. Burt RA. On gnats, camels, and payment to research subjects: A comment. Journal of Medicine and Law. 2005;9:25 -30. 
49. Grant RW, Sugarman J. Ethics in human subjects research: Do incentives matter? Journal of 
Medicine and Philosophy. Dec 2004;29(6):717- 738.  
50. Dickert N, Grady C. What's the price of a research subject? Approaches to payment for research 
participation. N Engl J Med. 1999;341:198 -203.  
51. Halpern SD, Raz A, Kohn R, Rey M, Asch DA, Reese P. Regulated payments for living kidney 
donation: an empi[INVESTIGATOR_111487]. Ann Intern Med. Mar 16 
2010;152(6):358- 365.  
52. Kim S, Kim H, McCallum C, Tariot P. What do people at risk f or Alzheimer disease think about 
surrogate consent for research? Neurology. 2005;65:1395 –1401.  
53. Karlawish J, Rubright J, Casarett D, Cary M, TenHave T, P S. Older adults’ attitudes toward non -
competent subjects participating in Alzheimer's research. Ame rican Journal of Psychiatry. 
2009;166(2):182- 188.  
54. Muroff J, Hoerauf S, Kim S. Is psychiatric research stigmatized? An experimental survey of the 
public. Schizophrenia Bulletin. 2006;32:129 -136.  
55. Henderson GE. Is Informed Consent Broken? American Journal of the Medical Sciences. Oct 
2011;342(4):267- 272.  
56. Bialkova S, van Trijp HCM. An efficient methodology for assessing attention to and effect of 
nutrition information displayed front -of-pack. Food Quality and Preference. 2011;22:592 –601.  
57. Pi[INVESTIGATOR_3689]  R, Warlop L. Visual attention during brand choice: The impact of time pressure and task 
motivation. International Journal of Research in Marketing. 1999;16:1 -16. 
 
 
 
90 
 58. Munafò MR, Roberts N, Bauld L, Leonards U. Plain packaging increases visual attention to health 
warnings on cigarette packs in non -smokers and weekly smokers but not daily smokers. Addiction. 
2011;106(8):1505– 1510.  
59. Kim SH WR, De Vries R, Kim H, Holloway R, Kieburtz K. Could the High Prevalence of Therapeutic 
Misconception Partly Be a Measu rement Problem? IRB: Ethics & Human Research 2015;37(4):11.  
60. Kim SH SL, Wilson RM, Frank SA, Holloway RG, Keiburtz K, De Vries RG. An Approach to Evaluating the Therapeutic Misconception. IRB: Ethics & Human Research. 2009;31(5):[ADDRESS_124246], et al. Therapeutic misconception, misestimation and optimism in 
subjects enrolled in phase I trials. Cancer. 2012;18(118):4571 -4578.  
62. Gardner W, Hoge SK, Bennett N, et al. Two scales for measuring patients’ perceptions for coercion durin g mental hospi[INVESTIGATOR_063]. Behavioral Sciences and the Law 1993;11:307- 321.  
63. Shea JA, Micco E, Dean L, McMurphy S, Schwartz SJ, Armstrong K. Development of a revised health care system distrust scale. Journal of General Internal Medicine. 2008;6(23):7 27-732.  
64. Israni AK, Halpern SD, McFadden C, et al. Willingness of dialysis patients to participate in a 
randomized controlled trial of daily dialysis. Kidney International. Mar 2004;65(3):990- 998.  
65. Shea JA ME, Dean LT, McMurphy S, Schwartz JS, Armstrong K. . Development of a Revised Health 
Care System Distrust Scale. Journal of General Internal Medicine. 2008;26(6):[ADDRESS_124247] of two separate, but similarly designed, embedded randomized trials within actual parent 
clinical trials. This Original Statistical Analysis plan was finalized after the decision to remove the RETAIN collaboration with RTOG1308, but before the enrollment of participants in BASC or MOVE IT. It is our 
hope the findings from this study will inform research regulations and guide the use of incentives in future RCTs so as to expedite medical innovation and improve health . 
 
2. Objectives and hypothes es 
 
The aims of this study are to (1) determine if the ethical concerns with incentives for research 
participation actually manifest; and (2) assess the possible scientific and ethical benefits of financial 
incentives for RCT participation.  
We hypothesize that research incentives will:  
• Augment participants’ perceptions of risk without disproportionately encouraging economically 
disadvantaged participants to enroll  
• Demonstrate an increased enrollment fraction in the parent trials, thereby [CONTACT_111578]  
 
3. Design and randomization  
RETAIN comprises two prospective randomized controlled trials, embedded  within two parent trials 
conducted in parallel, each comparing three intervention arms. Arms vary by [CONTACT_111579]. Amounts offered differ on a per trial basis 
determined by [CONTACT_111580]. 
Assignment to arms is determined by [CONTACT_111581] -number generation with block 
randomization using variable block sizes of [ADDRESS_124248] a 33.3 % 
probability of being assigned to each RETAIN arm.  
 
 
 
92 
  
a.   BASC Trial  
• The Behavioral Activation and Varenicline for Smoking Cessation in Depressed 
Smokers Study (BASC) (NCT 02378714)  
• Tests two behavioral interventions in combination with Varenicline in a p opulation 
of daily smokers with current or lifetime major depressive disorder  
• Eligible patients are randomized to receive inform consent forms offering $0, $200, 
or $500 incentives for participation  
• Patients are enrolled at The University of Pennsylvania and Northwestern 
University; randomization is stratified by [CONTACT_3725]  
 
b. MOVE IT Trial  
• The Mobility and Outcomes for Validated Evidence –  Incentive Trial (MOVE IT) (NCT 
03321279)  
• Aims to examine the impact of a supportive social incentive -based gamification 
inter vention in the three months post- hospi[INVESTIGATOR_111500]  
• Eligible patients are randomized to receive inform consent forms offering $0, $100, 
or $300 incentives for participation  
• Patients are e nrolled at the Hospi[INVESTIGATOR_111501] a team of 
clinical research coordinators; randomization is stratified by [CONTACT_111582], clinical research coordinators administering the consent process in both pare nt trials are 
unmasked to the incentive information being messaged to prospective participants. The introduction to 
the study and the informed consent process have been robustly scripted for research staff involved in 
both trials to ensure that messaging is consist ent and biases are minimized.   
4. Population  
Eligibility for RETAIN is contingent on eligibility for the BASC and MOVE IT parent trials.  
 
 
 
93 
 • Adults age 18 years or older who are daily smokers with current or lifetime major depressive 
disorder without psychotic features (BASC)  
• Adults age 18 years or older who are admitted for inpatient care to the Hospi[INVESTIGATOR_71972] (HUP) on medicine or oncology floors (MOVE IT)  
Patients randomized to RETAIN must be:  
• Eligible for parent RCT  
• 18 ye ars or older 
• English -speaking 
In the BASC trial, prior knowledge of the incentive randomization or payment equalization used for this 
study, which will be assessed with open -ended prompts during the first encounter, is an exclusion 
criterion. We will not a ssess for prior knowledge in the inpatient MOVE IT study population. However, 
only one patient per hospi[INVESTIGATOR_111502].  
5. Primary outcome and analytic method  
a. Primary outcome  
The primary out come is the proportion of participants assigned to each incentive amount that consent 
to enroll in each of the two parent RCTs.  
b. Primary analytic sample  
Intention -to-treat (ITT) approach such that the analytic sample will include all patients randomized in  
the RETAIN trial, even if ultimately deemed ineligibile for the parent trials . 
c. Primary analysis  
We will first assess bivariate relationships of incentives with the primary outcome using chi- square tests 
for comparisons of proportions. To examine the hypothesized statistical interactions, we will use logistic, 
linear, or quantile regression, as appropriate based on outcome parameterizations and distributions. For 
all outcomes other than tests for undue or unjust inducement, we will adjust significance levels for 
multiple comparisons using the Holm method.  
In all analyses in which the parent trial enrolls in multiple centers, we will model the center from which 
patients are recruited as a fixed effect, thereby [CONTACT_111583]. To adjust for chance covariate imbalance among 
 
 
 
94 
 arms, primary analyses will include covariates (see Table 1) in multivariable models if they are 
significantly associated  with the intervention arm and predictive of enrollment in the parent trials in 
bivariate analyses. To avoid problems in estimating odds ratios due to sparse data, we will limit the 
number of covariates to no more than [ADDRESS_124249] inducements entail three primary covariates: risk perception, 
annual household income, and economic well -being. All models will use enrollment in the parent trial as 
the outcome.  To determine if incentives represent undue inducements for research participation, we 
will test the statistical interaction between incentive size and the primary covariate of risk perception on 
the outcome of enrollment in the parent trials.  We will test two interactions, each in a separate model 
to avoid collinearity, to determine if incentives represent unjust inducements: that between incentive size and the primary covariate of annual household income, and that between incentive size and the 
primary covariate of economic well- being.  All analys es will be stratified by [CONTACT_111584].  
Analyses of interaction terms will be structured as tests of non -inferiority. The null hypothesis, for both 
trials, will be that the use of incentives meets criteria for undue or unjust inducement. We can reject the 
null, and conclude the absence of undue or unjust inducement, if the interaction terms are “small” 
according to pre -specified criteria (in technical terms, the inferiority margin). Said a different way, our 
analyses are designed to determine if we can exclude the possibility that incentives represent undue or 
unjust inducements if the resulting interaction terms are sufficiently small. Specifically, we will use one -
sided alpha levels of 0.05 to exclude, with 95% confidence, the possibility that any of these  interaction 
odds ratios are >2.0.   
We will explore temporal trends in incentives’ effects over the study period using stratified analyses. If temporal trends are noted, as may occur if prospective patients learn of the incentives used in these 
studies, w e will adjust for their influence by [CONTACT_111585] a covariate, modeled as a spline. We will 
evaluate potential effect modifiers (variables in Table 1) using stratified analyses. If differences among strata appear, we will formally test their correspond ing interactions with the incentive amount.  
 
 
 
 
 
[ADDRESS_124250] MOD IFICATION 
 
  
  
 
 
 
 
 
6. Approach to missing data & sensitivity analyses   
In addition to introducing several modifications to enrollment procedures to safeguard against missing 
data, some guidelines have been implemented to address missing data. The study team is particularly 
concerned about missingness of key RETAIN outcomes du e to post -randomization ineligibility (i.e. a 
patient is discovered to be ineligible for the parent trial after randomization into RETAIN).  If missingness due to parent trial ineligibility does not exceed 10%, the primary analysis will be limited to participants with complete data.  
If missingness due to parent trial ineligibility is greater 10%, logistic models will be fit separately among 
observed data within each arm with the consent decision (yes or no) as the outcome and screening 
variables as predictors.  For each ineligible participant, the probability of consent will then be determined according to the intervention -specific models and their respective screening covariates.  
Binary consent outcomes will then be generated for ineligible participants, and outcome generation will be repeated within the context of a multiple imputation algorithm.  
In the event that our primary analyses include imputed data, sensitivity analyses will evaluate the robustness of our conclusions.  Specifically, sensitivity analyses will vary the intercept parameter in the 
models used to generate outcomes for post- randomization ineligibles so that they are more or less likely 
to consent than subjects with observed outcomes. We will assume, however, that covariate effects on 
cons ent are the same.  The intercept parameter will be varied using a minimum of 5 different values per 
arm. These values will be chosen such that the average probability of consent within arm spans the Potential factors for adjustment  
Patient level covariates  Variable coding or 
definition  
 Age Continuous  
 Gender  Binary  
 Race  Categorical  
 Marital status  Categorical  
 Education  Categorical  
 Income  Categorical  
 Economic well -being  Categorical 
 Prior research participation  Categorical  
 Attitudes towards research:  Continuous, measured using 
the Research Attitudes 
Questionnaire-7 (RAQ -7). 
 
 
 
96 
 range (0,1) and gives sufficient information to informally assess which assumptions would influence the 
results of the primary analysis. For each combination of parameter values, estimates will be obtained 
using the same techniques as described above for the primary analysis.  
We do not anticipate substantial mis sing data beyond that which is due to ineligibility, as most 
outcomes are assessed by [CONTACT_111586]. Nonetheless, it is possible that participants may not complete certain po rtions of the 
instruments measuring the outcomes of interest. We will explore and potentially adjust for missing 
values using pattern -mixture methods and multiple imputation models in secondary analyses.  
 
7. Secondary Outcomes  
a. Outcome measures  
Attention to th e informed consent document : We will assess the amount of time patients spend 
reading each part of the parent trial consent form by [CONTACT_111523] a “survey” in REDCap. 
The data extract will include the time – to the second – at which the parti cipant moved to another 
section through a timestamp.  The primary measure of this assessment will be time spent on the risk section; the secondary measure will be total time spent on the consent form.  
Perceived risks of the research:  Perceived risks of the  research will be measured by a modified 9 -item 
“compared riskiness” scale, which has been used in previous studies and refined for the RETAIN trial.  
Incidence of therapeutic misconceptions: It has been hypothesized that the use of financial incentives 
could reduce therapeutic misconceptions, and thereby [CONTACT_111587] -making. Because 
patients are not accustomed to being paid for their clinical care, offering incentives could signal that research is different.  We will test the hypothesized benef it of research incentives by [CONTACT_111588]. We will assess this outcome with a [ADDRESS_124251]. Scott Kim.  
Understanding of the trial:  To assess whether increased attention translates into improved 
understanding of the trial, we will use a 6 -item Trial Elements Quiz, featuring core elements of the 
parent trials’ consent forms.   
Perceptions of influence or coercion:  To measure g eneral perception of coercion and voluntariness of 
research participation, we will use the five -item Perceived Coercion Scale of the MacArthur Admission 
 
 
 
97 
 Experience Survey.  
Retention through the end of treatment sessions: To assess the impact of incentives  on retention 
status in the protocol, we will disburse payment in two installments - one as soon as possible after 
debriefing and one during the patient’s last week of treatment therapy or study intervention. The 
denominator for analyses of this outcome will be all those who received the first payment. We will 
assess if patients completed their treatment, and if not, reasons for non -completion.  
b. Analysis of secondary outcomes  
We will first test the bivariate relationships between incentives and secondary outcomes using ANOVA or Kruskal- Wallis/Wilcoxon rank -sum tests for normally and non -normally distributed continuous 
variables, and chi- square tests for comparisons of proportio ns. To assess the outcomes with 
adjustments, we will use logistic, linear, or quantile regression, as appropriate based on outcome parameterizations and distributions. We will adjust significance levels for multiple comparisons using the Holm method.  
 
 
 
 
[ADDRESS_124252] incentive. With an overall 
sample size of 576 participants in each parent study involved in the RETAIN trial, we assumed that 192 
participants would be randomized to each of the 3 incentive arms. Assuming that  randomization balances 
the incentives distribution within each risk -perception group, 96 participants will be assigned to each of the 
3 incentives within both the high and low risk -perception groups. Among patients assigned to receive $0, 
we set the OR co ntrasting the odds of enrollment between risk -perception groups to 1, such that the OR for 
those assigned to receive the highest incentive ($300 or $500, in MOVE IT and BASC, respectively) represents the interaction odds ratio. We assume a true interaction  OR of 1, and use a one -sided 
significance level of 0.0427 such that the upper 95.73% confidence limit on the observed OR falls entirely 
below the non -inferiority threshold. If the enrollment rate in the parent trials is 50%, we will have at least 
80% powe r to rule out undue inducement, as represented by [CONTACT_111589] 2.[ADDRESS_124253] inducement interaction terms.  
 
9. Data Safety & Monitoring Board (DSMB)  
We have chartered a DSMB to monitor RETAIN, with purview over both embedded trials, for the expressed 
purpose of evaluating evidence of undue or unjust inducement.  Any serious adverse events, protocol 
deviations/violations, and unanticipated events will b e reported to the IRBs with oversight of recruiting 
 
 
 
[ADDRESS_124254] for the following events: 
I. Undue inducement  
To detect if incentives represent undue inducement that could distort voluntary informed 
consent, the research team will test the statistical interaction between incentive size and risk perception on the outcome of enrollment in the parent RCT.  
II. Unjust inducement  
To asses s the presence of unjust inducement, or preferential participation among participants 
with either (a) lower income, or (b) reduced financial well- being, two interaction terms will be 
evaluated in separate models to avoid collinearity. Unjust inducement will be defined as a statistically significant interaction between (a) incentive size and annual household income, or (b) between incentive size and economic well -being, each on the outcome of trial enrollment. 
One or both of these interactions, if statistica lly significant in the direction that lower- income 
persons or persons with reduced economic well -being are more strongly motivated to 
participate by [CONTACT_111575], will be considered grounds for terminating the trial 
or suspending a trial arm . 
 
11.    Timing of analysis and adjustment of significance level  
Interim analyses will be conducted after 50% and 75% of the data have accrued within each the BASC and 
MOVE IT trials. In contrast to the final analyses, which will be structured as tests of non -inferiority, the 
interim analyses will be conducted as superiority tests of the interactions, such that rejection of the null hypothesis indicates evidence of the presence of an interaction between incentive size and one of our three primary covariates. W e will use 1 -sided significance levels of 0.0055, and 0.0219.  
12.    Personnel  
Interim analyses will be performed by [CONTACT_20767]’s primary statistician  who will conduct all analyses blinded to 
trial arm. Investigators, the project manager, and the DSMB will remain blinded to treatment arm through completion of analyses. The data manager and faculty statistician have been unblinded as was necessary to perform essential functions of their roles.  
 
 
 
100 
   
 
 
 
101 
 V. Changes to Statistical Analysis Plan  
Date  Change  Reason for change  
1/27/[ADDRESS_124255], 
there was no role 
for ‘Holm’ 
adjustment for multiple testing  
as this was a 
single test .  The incentives are in increasing order and tests with an ordered 
variable have only a single contrast, obviating the need for 
adjustment .  
1/27/[ADDRESS_124256] is the appropriate statistic for non -parametric data, 
rather than the Kruskal Wallis.  
1/27/[ADDRESS_124257] outlier and influential 
observations.  The compared riskiness data were observed to be very sparse  in the 
higher -risk ranges , particularly in the Ambulation trial. This 
diagnostic was designed to ensure that inference s were not driven 
by a few influential observations.  
1/27/[ADDRESS_124258] -consent instruments, so the re was 
no basis for including non -consenting patients in tests of secondary 
outcomes. Instead, we limit our contrasts to those among incentive 
arms amo ng the consenting patients.  
 
 
 
 
102 
 1/27/2020  Secondary 
outcomes were 
analyzed 2 ways 
for both trials: 
Primary approach - 
Unweighted; Secondary 
approach – 
adjusted for 
response rate using propensity 
weights.  These outcomes are analyzed among the consented sample 
because of aforementioned limitation s in capturing secondary 
outcomes . Participants who consented and didn’t consent might be 
different and non -response might not be at random. To check if the 
inferenc e is robust we planned for both analyses.  
2/17/2020  Included 
secondary analysis of the risk score and incentives where 
risk score is 
treated as a binary variable (0 
and >0).  During the interim analyses we gained  meaningful insight into the 
risk score distributions. We found that in the Ambulation trial the 
risk score mostly (>85%) clump ed on [ADDRESS_124259] of two separate, but similarly designed, embedded randomized trials withi n actual parent 
clinical trials. It is our hope the findings from this study will inform research regulations and guide the 
use of incentives in future RCTs so as to expedite medical innovation and improve health  
 
2. Objectives and hypotheses  
The aims of this  study are to (1) determine if the ethical concerns with incentives for research 
participation actually manifest; and (2) assess the possible scientific and ethical benefits of financial incentives for RCT participation.  
We hypothesize that research incentives will:  
• Augment participants’ perceptions of risk without disproportionately encouraging economically 
disadvantaged participants to enroll  
• Demonstrate an increased enrollment fraction in the parent trials, thereby [CONTACT_111590]  
 
3. Design and randomization  
RETAIN comprises two prospective randomized controlled trials, embedded  within two parent trials 
conducted in parallel, each comparing three intervention arms. Arms vary by [CONTACT_111579]. Amounts offered differ on a per trial basis 
determined by [CONTACT_111580]. 
Assignment to arms is determined by [CONTACT_111581] -number generation with block 
randomization using variable block sizes of [ADDRESS_124260] a 33.3%  
probability of being assigned to each RETAIN arm.  
 
a.   BASC Trial  
• The Behavioral Activation and Varenicline for Smoking Cessation in Depressed Smokers 
Study (BASC) (NCT 02378714)  
 
 
 
104 
 • Tests two behavioral interventions in combination with Varenicline in a po pulation of 
daily smokers with current or lifetime major depressive disorder  
• Eligible patients are randomized to receive inform consent forms offering $0, $200, or 
$500 incentives for participation  
• Patients are enrolled at The University of Pennsylvania and Northwestern University; 
randomization is stratified by [CONTACT_3725]  
 
b. MOVE IT Trial  
• The Mobility and Outcomes for Validated Evidence –  Incentive Trial (MOVE IT) (NCT 
03321279)  
• Aims to examine the impact of a supportive social incentive -based gamification 
intervention in the three months post- hospi[INVESTIGATOR_111503]  
• Eligible patients are randomized to receive inform consent forms offering $0, $100, or 
$300 incentives for participation  
• Patients are enrolled at the Hospi[INVESTIGATOR_111501] a team of 
clinical research coordinators; randomization is stratified by [CONTACT_111591]  
• By [CONTACT_111592], clinical research coordinators administering the consent process in both 
parent trials are unmasked to the incentive information being messaged to prospective 
participants. The introduction to the study and the informed consent process have been 
robustly scripted for research staff involved in both trials to ensure that messaging is 
consistent and biases are minimized.   
 
4. Population  
Eligibility for RETAIN is contingent on eligibility for the BASC and MOVE IT parent trials.  
• Adults age 18 years or old er who are daily smokers with current or lifetime major depressive 
disorder without psychotic features (BASC)  
• Adults age 18 years or older who are admitted for inpatient care to the Hospi[INVESTIGATOR_71972] (HUP) on medicine or oncology floors (MOVE IT) 
Patients randomized to RETAIN must be:  
• Eligible for parent RCT  
• 18 years or older  
• English -speaking 
In the BASC trial, prior knowledge of the incentive randomization or payment equalization used for this 
 
 
 
[ADDRESS_124261] agains t 
contamination.  
 
5. Primary outcome and analytic method  
a. Primary outcome  
The primary outcome is the proportion of participants assigned to each incentive amount that consent 
to enroll in each of the two parent RCTs.  
b. Primary analytic sample  
Intention -to-treat (ITT) approach such that the analytic sample will include all patients randomized in 
the RETAIN trial, even if ultimately deemed ineligib le for the parent trials.  
c. Primary analysis  
We will first assess bivariate relationships of incentives with the primary outcome using chi -square tests 
for comparisons of proportions. To examine the hypothesized statistical interactions, we will use logistic, linear, or quantile regression, as appropriate based on outcome parameterizations and distributions.  In 
the above analyses we treated incentive as an ordered variable. In all analyses in which the parent trial enrolls in multiple centers, we will model the center from which patients are recruited as a fixed effect, 
thereby [CONTACT_111593] g variance estimates for clustering of participants 
within centers. To adjust for chance covariate imbalance among arms, primary analyses will include 
covariates (see Table 1) in multivariable models if they are significantly associated  with the interventi on 
arm and predictive of enrollment in the parent trials in bivariate analyses. To avoid problems in 
estimating odds ratios due to sparse data, we will limit the number of covariates to no more than [ADDRESS_124262] inducements entail three primary covariates: risk perception, 
annual household income, and economic well -being. All models will use enrollment in the parent trial as 
the outcome.  To determine if incentives represent undue i nducements for research participation, we 
will test the statistical interaction between incentive size and the primary covariate of risk perception on 
 
 
 
[ADDRESS_124263] inducements: that between incentive 
size and the primary covariate of annual household income, and that between incentive size and the primary covariate of economic well- being.  All analyse s will be stratified by [CONTACT_111584].  
Analyses of interaction terms will be structured as tests of non -inferiority. The null hypothesis, for both 
trials, will be that the use of incentives meets criteria for undue or unjust inducement. We can reject the 
null, and conclude the absence of undue or unjust inducement, if the interaction terms are “small” 
according to pre -specified criteria (in technical terms, the inferiority margin). Said a different way, our 
analyses are designed to determine if we can exclu de the possibility that incentives represent undue or 
unjust inducements if the resulting interaction terms are sufficiently small. Specifically, we will use one -
sided alpha levels of 0.05 to exclude, with 95% confidence, the possibility that any of these interaction odds ratios are >2.0.   
We will explore temporal trends in incentives’ effects over the study period using stratified analyses. If temporal trends are noted, as may occur if prospective patients learn of the incentives used in these 
studies, we  will adjust for their influence by [CONTACT_111585] a covariate, modeled as a spline. We will 
evaluate potential effect modifiers (variables in Table 1) using stratified analyses. If differences among strata appear, we will formally test their corresponding interactions with the incentive amount.  
 
 
  
  
 
  
 
 
 
[ADDRESS_124264] MOD IFICATION  
 
    
 
       
 
 
6. Secondary analysis  
We will implement secondary interaction analyses of risk score with incentive arm. Risk score will be 
treated as binary variable with 0 and >[ADDRESS_124265] ion c. We plan to compare the inference of this analysis 
with the primary approach and report accordingly.   
a. Approach to outliers and influential observations  
We plan to perform diagnostic checks for influential and outlier observations in interaction analyses. The analyses will be done both ways including and then excluding influential observations if any is detected. 
To implement the diagnostic process we will use ‘car’ package from R.  
b. Secondary outcome measures  
Attention to the informed consent document : We will assess the amount of time patients spend 
reading each part of the parent trial consent form by [CONTACT_111523] a “survey” in REDCap. 
The d ata extract will include the time – to the second – at which the participant moved to another 
section through a timestamp.  The primary measure of this assessment will be time spent on the risk section; the secondary measure will be total time spent on the consent form.  Potential factors for adjustment  
Patient level covariates   Variable coding or 
definition  
 Age Continuous  
 Gender  Binary  
 Race  Categorical  
 Marital status  Categorical  
 Education  Categorical  
 Income  Categorical  
 Economic well -being  Categorical 
 Prior research participation  Categorical  
 Attitudes towards research:  Continuous, measured 
using the Research 
Attitudes Questionnaire -7 (RAQ-
7). 
 
 
 
108 
 Perceived risks of the research:  Perceived risks of the research will be measured by a modified 9 -item 
“compared riskiness” scale, which has been used in previous studies and refined for the RETAIN trial.  
Incidence of therapeutic misconcept ions:  It has been hypothesized that the use of financial incentives 
could reduce therapeutic misconceptions, and thereby [CONTACT_111587] -making. Because 
patients are not accustomed to being paid for their clinical care, offering incentives could signal that 
research is different.  We will test the hypothesized benefit of research incentives by [CONTACT_111588]. We will assess this outcome with a [ADDRESS_124266]. Scott Kim.  
Understanding of the trial: To assess whether increased attention translates into improved 
understanding of the trial, we will use a 6 -item Trial Elements Quiz, featuring core elements of the 
parent trials’ consent forms.   
Perceptions of influence or coercion:  To measure general perception of coercion and voluntariness of 
research participation, we will use the five -item Perceived Coercion Scale of the MacArthur Admission 
Experience Survey.  
Retention thr ough the end of treatment sessions: To assess the impact of incentives on retention 
status in the protocol, we will disburse payment in two installments - one as soon as possible after 
debriefing and one during the patient’s last week of treatment therapy o r study intervention. The 
denominator for analyses of this outcome will be all those who received the first payment. We will 
assess if patients completed their treatments is associated to incentive amounts.  
c. Analysis of secondary outcomes  
We will first tes t the bivariate relationships between incentives and secondary outcomes using ANO VA 
or Jonckheere -Terpstra test for normally and non -normally distributed continuous variables, and chi-
square tests (trend tests) for comparisons of proportions. In all of the se analyses the incentive arm was 
included as an ordered variable. All the secondary outcomes are assessed among participants who 
consented for the trials. Due to limited sample size we plan to perform the unadjusted analyses.  
Participants who consented and who didn’t might be different meaning non response might not be 
random. To check if the inference is robust or not we plan to analyze the appropriate secondary 
outcomes 2 ways - unweighted and weighted. In survey weighted approach we plan to use propens ity 
scores (inverse of probability of consent) as weights.  
 
7. Sample  size and statistical power calculations  
 
a. Sample size  
We plan to enroll [ADDRESS_124267] incentive. 
With an overall sample size of 576 participants in each parent study involved in the RETAIN trial, we assumed that 192 participants would be randomized to each of the 3 incentive arms. Assuming that 
randomization balances the incentives distribution within each risk -perception group, 96 participants 
will be assigned to each of the 3 incentives within both the high and low risk -perception groups. Among 
patients assigned to receive $0, we set the OR contrasting the odds of enrollment between risk-
perception groups to 1, such that the OR for those assigned to receive the highest incentive ($300 or 
$500, in MOVE IT and BASC, respectively) represe nts the interaction odds ratio. We assume a true 
interaction OR of 1, and use a one -sided significance level of 0.0427 such that the upper 95.73% 
confidence limit on the observed OR falls entirely below the non -inferiority threshold. If the enrollment 
rate in the parent trials is 50%, we will have at least 80% power to rule out undue inducement, as 
represented by [CONTACT_111589] 2.[ADDRESS_124268] similar levels of power to rule out the unjus t 
inducement interaction terms.  
8. Data Safety & Monitoring Board (DSMB)  
We have chartered a DSMB to monitor R ETAIN, with purview over both embedded trials, for the 
expressed purpose of evaluating evidence of undue or unjust inducement.  Any serious adverse events, 
protocol deviations/violations, and unanticipated events will be reported to the IRBs with oversight  of 
recruiting sites, the DSMB, and The National Cancer Institute.  
 
9. Stoppi[INVESTIGATOR_111504]: 
a. Undue inducement  
To detect if incentives represent undue inducement that could distort voluntary informed consent, the research team will test the statistical interaction between incentive size and risk perception on the outcome of enrollment in the parent RCT.  
b. Unjust ind ucement  
 
 
 
[ADDRESS_124269] inducement, or preferential participation among participants with 
either (a) lower income, or (b) reduced financial well- being, two interaction terms will be evaluated in 
separate models to avoid collinearity. Unju st inducement will be defined as a statistically significant 
interaction between (a) incentive size and annual household income, or (b) between incentive size and economic well- being, each on the outcome of trial enrollment. One or both of these interactio ns, if 
statistically significant in the direction that lower- income persons or persons with reduced economic 
well- being are more strongly motivated to participate by [CONTACT_111575], will be considered 
grounds for terminating the trial or suspe nding a trial arm.  
 
10.    Timing of analysis and adjustment of significance level  
Interim analyses will be conducted after 50% and 75% of the data have accrued within each the BASC and MOVE IT trials. In contrast to the final analyses, which will be structure d as tests of non -inferiority, 
the interim analyses will be conducted as superiority tests of the interactions, such that rejection of the null hypothesis indicates evidence of the presence of an interaction between incentive size and one of 
our three prim ary covariates. We will use 1 -sided significance levels of 0.0055, and 0.0219.  
 
11.    Personnel  
Interim analyses will be performed by [CONTACT_20767]’s primary statistician who will conduct all analyses 
blinded to trial arm. Investigators, the project manager, and the DSMB will remain blinded to treatment 
arm through completion of analyses. The data manage r and faculty statistician have been unblinded as 
was necessary to perform essential functions of their roles.  
 
 
 